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ABSTRACT
Complex diseases and disorders pose a challenge to scientists due to their variable and
often inconsistent genetic and environmental underpinnings across affected individuals.
Because of this variability, large condition-specific datasets and corresponding analytical
tools and approaches are being curated as resources to investigate potential genetic trends
in complex diseases and disorders. In this Dissertation, I used DNA- and RNA-based
resources to discover polygenic biosignatures associated with Autism Spectrum Disorder
(ASD) or uterine cancer. To explore the intersection of small-effect common DNA
variants and regulation in ASD, I discovered and analyzed trends in allelic associations at
eQTLs within ASD-affected individuals. Association of eQTLs underlying any
phenotype brings the genetic variation closer to biochemical mechanism leading to
phenotypic expression. Uterine cancer was additionally investigated using gene
expression profiles from normal and cancerous uterine tissue samples, from which gene
co-expression networks and corresponding gene regulatory networks were built and
further studied. The biomarker discoveries discussed here reflect the importance of dry
lab resources and the potential they hold for future discovery.
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CHAPTER ONE
LITERATURE REVIEW OF AUTISM SPECTRUM DISORDER, UTERINE
CANCER, AND BIOMARKER DISCOVERY TECHNIQUES

Introduction
Complex diseases are those controlled by multiple genetic and/or environmental
factors, the combination of which often differ between diagnosed individuals (1). Many
large-effect common genetic mutations have been identified in complex diseases, such as
the infamous BRCA1 and BRCA2 mutations in breast cancer. However, only 10-30% of
breast cancer samples display those mutations (2). The variability in genetic and
environmental control across cases is a common trend in complex diseases and creates
challenges for investigative research. The challenges lie in identifying the potential
causes for affected individuals, as complex diseases are inconsistent in their underlying
factors. One approach to confront the challenges presented by complex diseases is
through the comparison of genetic characteristics between affected and unaffected
individuals. By surveying resources containing large groups of individuals, there is more
power to identify underlying genetic factors. Therefore, these challenges can be further
addressed through the integration and subsequent analysis of relevant big data resources
using bioinformatic techniques and tools. In this Dissertation, I will discuss investigations
into the genetic characteristics of two independent complex disorders: Autism Spectrum
Disorder (ASD) and uterine cancer.
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ASD is a complex neurodevelopmental disorder with a variety of genetic
associations, environmental risk factors, and comorbidities (3). ASD is heterogeneous in
its presentation but will most commonly appear in conjunction with traits like repetitive
behaviors, difficulties in social communication, and sensory sensitivities (3). Many largescale genetic associations have been identified but are only present in 20% of ASDaffected individuals (4). To further elucidate other possible genetic associations, I
investigated allelic patterns at regulatory loci in ASD-affected individuals, which is
further described in Chapter 2.
Another complex disease investigated in this Dissertation is a subtype of uterine
cancer known as endometrial cancer. Endometrial cancer can appear as an endometrioid
carcinoma, serous adenocarcinoma, or uterine carcinosarcoma, among others (5,6).
Similar to ASD, there have been common genetic mutations identified, like those in
PTEN and TP53 (7). Rather than honing in on specific genes, I built condition-specific
gene-coexpression and gene regulatory networks to analyze common expression patterns
within and across subtypes. This analysis is further described in Chapter 3.
This literature review chapter will investigate the background characteristics of
these complex conditions and discuss relevant datasets and computational tools utilized
for condition-specific biomarker discovery.

Autism Spectrum Disorder
ASD is a heterogeneous neurodevelopmental disorder characterized by repetitive
or restricted behaviors and challenges in social communication and interaction (3,8).
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These behaviors can manifest as difficulties in exchanging conversation or understanding
non-verbal cues, intense interests in specific topics, atypical sensory experiences, and
echolalia, among many other traits (8,9). Parents can observe these characteristics in
their child as early as 15-18 months, but the age of diagnosis usually falls between 2 and
7 years old (3,10,11). Not only do the range of traits in autistic individuals vary greatly,
but the severity does as well. For example, communication from completely non-verbal
to another participating in normal conversations. Another salient characteristic of ASD is
the disparate ratio in gender. Females are diagnosed much less often than males (between
1:3 or 1:4), and it is often more difficult for them to be diagnosed because they are
usually better at mirroring their peers in social interactions (3,12). In addition to the
managing the traits associated with ASD, ASD-affected individuals are also more likely
to have other health challenges compared to controls (13).
ASD-affected individuals are at a higher risk of developing other
neurodevelopmental disorders, including ADHD (14), depression (15), and bipolar
disorder (15), as well as non-brain conditions including obesity (16), allergy disorders
(17), and cardiac arrhythmia (18). Studies have found that the majority of ASD-affected
individuals have at least one psychiatric comorbidity (19,20). For individuals with
comorbid brain disorders, there could be a singular genetic cause that leads to the
appearance of more than one disorder, known as a large-effect mutation. For example,
mutations in proteins have been identified that specialize in synaptic development and
plasticity (21,22).
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ASD is a highly heritable disorder, with heritability estimates ranging between
50%-83% (23,24). While many twin studies have been conducted to investigate the
prevalence of ASD among families, traits associated with ASD have been found to run in
families, even in family members without an official diagnosis. This is known as the
‘broader autism phenotype’ (25,26). Studies have shown that ASD-unaffected relatives of
probands have performed significantly below normal in a test designed to assess
executive function (27), have more difficulty in social communication compared to
controls (28,29), and are more likely to have a language delay (30). This can vary based
on the type of family as well. Simplex families, where only one individual has been
diagnosed with ASD, seem to be influenced more often by rare, de novo genetic events,
and have fewer family members with the broader autism phenotype (30–33). However,
multiplex families, with more than one ASD-affected individual, are likely more
influenced by the accumulation of many small-effect variations, and more likely to have
family members that exhibit ASD-associated traits without having an official
diagnosis (26–28,30). While a single small-effect mutation will not result in the
phenotype, the accumulation of them may predispose risk. Overall, these genetic changes
can be characterized as large chromosomal aberrations, copy number variations (CNVs),
single gene associations, or the accumulation of common variation.
Large chromosomal aberrations have been associated with ASD-affected
individuals. One example includes individuals with a comorbid diagnosis of both ASD
and Down Syndrome (trisomy 21). It has been hypothesized that the rate of ASD in those

4

with Down’s Syndrome falls around 10% (35,36). Duplications and deletions can also
occur in ASD-affected individuals on a smaller scale, such as with CNVs.
CNVs are duplications or deletions of regions of genetic material and have been
associated with 5-10% of idiopathic ASD cases (37–39). These have been found to vary
in size, with events as small as 150bp and as large as 13mb (40,41). CNVs can impact
expression of involved and neighboring genes, and tend to cluster near genes involved in
neural-related pathways in ASD-affected individuals more often than ASD-unaffected
siblings (41). At least forty recurrent CNVs have been associated with ASD, and while
penetrance is high, they do not always confer a neurodevelopmental phenotype, as they
have also been found in ASD-unaffected parents of ASD probands (38,42,43). CNVs also
contribute to syndromic types of ASD, such as 15q11-13 with Prader-Willi and
Angelman syndrome and 22q13 with Phelan-McDermid syndrome (38–40). In addition
to CNVs, autism risk is also conferred by mutations in single genes.
The mutations that commonly appear in the literature often affect single genes
controlling neuronal synapsis, transcriptional regulation, and chromosome remodeling
(47–49). Factors involved in neuronal synapsis include shank proteins and neuroligins,
such as SHANK2, SHANK3, NLGN3, NLGN4X, as well as others, like NRXN1,
SCN2A, and SYNGAP1 (47,50,51). These genes may be implicated through a mutation
that causes a protein-truncating variant or a change in the amino acid sequence. Studies
have shown that ASD-associated genes tend to be less tolerant of those
mutations (46,47). Genes that play a part in transcriptional regulation and chromatin
remodeling (like MBD1 and MECP2) have a potentially more pervasive effect due to
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their widespread involvement in control of gene expression (54,55). While coding
mutations can have an obvious effect on protein sequence, changes in transcriptional
levels due to mutations in regulatory regions of the DNA have also been implicated
(52,56).
One final group of mutations that contributes to ASD risk is that of common
variants (minor allele frequency  1%) (57). The association of common variants with
complex disorders has also been established (58,59). The accumulation of small-effect
common variants has been shown to play a larger role in conferring ASD risk than largeeffect CNVs or rare variants (34,59–61), but is more likely to contribute to heritability in
multiplex families compared to simplex families as described above (60). It has also been
suggested that common variants are more likely to be associated with higher functioning
ASD-affected individuals, while de novo variants are more likely to be found in ASDaffected individuals with comorbid intellectual disability (61). ASD-associated common
variants have been associated with gene regulation in developing neurons, and show
functional overlap with genes implicated by rare large-effect variants (61,62).
In addition to genetic studies, there have been studies conducted to investigate
physical characteristics of the brain associated with ASD using different types of
imaging. One observed brain characteristic is a change in overall brain surface area in
ASD-affected toddlers compared to controls (63,64), which may be due to disruptions in
neural connectivity, similar to patterns in ASD comorbidities: Angelman syndrome and
fragile X syndrome (65–67). Cortical thickness abnormalities have also been associated
with ASD and most likely change throughout the lifetime of ASD-affected individuals
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(68). Unusually small cell size in the amygdala and hippocampus have also been
observed, which are areas responsible for emotion regulation and memory (69). The
cerebellum has also been extensively studied in relation to ASD (70–72) and plays a role
in not only motor skills, but also higher-order functions (73). The Purkinje cells in the
cerebellum have also been observed to be decreased in ASD-affected individuals (69).
Purkinje cells project to the deep cerebellar nuclei where neurons seem to be enlarged in
young ASD-affected kids, but smaller, and sometimes fewer, in older ASD-affected
adults (74). This is important as the deep cerebellar nuclei serve as a method of
communication between the cerebellum and the cortex (73).
There have been investigations into brain regions related to information
integration and understanding social interactions, such as white matter, which plays a role
in learning (75,76), memory (75), information processing (76), and the corpus callosum,
which is important for cognitive function and integration (77). White matter has been
observed at an increased volume in the cortex of ASD-affected individuals, while the
corpus callosum was smaller than normal (78–80). This is consistent with other studies
looking into connectivity and integrity of white matter, which was found to be
significantly different between ASD-affected individuals and controls (81,82). However,
these changes have also been observed in siblings at risk for developing ASD but were
not affected (83). Therefore, it has been hypothesized that white matter changes may be
associated with ASD-risk, rather than a diagnosis (80). Meanwhile, Picci and colleagues
argue that the connectivity associations from other studies are not consistent enough to
make claims about the ASD-affected population as a whole (84). Clinical studies have
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been used to map genetic variations to changes in brain morphology and connectivity.
For example, polymorphisms in NRXN1 and CNTNAP2 were found to influence brain
connectivity in the frontal lobe (85,86). A common SNV in CD38 has been associated
with differences in neuronal and behavioral activity in social situations (87), while
variants in MET were related to changes in white matter connectivity and are therefore
implicated in working memory and language processing (88,89).
In summary, ASD is a complex neurodevelopmental disorder with a variety of
associated traits, genetic changes, and morphological characteristics. While many largescale genetic associations have been identified, the investigation of common variants
remains to be elucidated. In Chapter 2 of this Dissertation, I describe an analysis for
common variants at regulatory loci to discover genotypic trends in ASD-affected
individuals.

Uterine Cancer
ASD and uterine cancer are unrelated entities but are similar in that they are both
complex conditions with unique biomarker profiles. When moving into the uterine cancer
study from the ASD study, not only are the conditions and site of gene misexpression
different, but the type of investigation transitions as well. While the ASD expression
quantitative trait loci (eQTL) study in this Dissertation (Chapter 2) focused on significant
trends in gene expression control at the DNA level, the uterine cancer study (Chapter 3)
investigated condition-specific trends at the RNA expression level and, subsequently,
potential associations of regulatory mechanisms.
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Uterine cancer is the most common gynecological cancer in women, projected to
affect nearly 66,000 women in the United States in 2021, with numbers rising each year
(90,91). There are two primary places where uterine cancer can arise: tumors form in the
lining of the uterus, the endometrium, or the smooth muscle layer of the uterus, the
myometrium (Figure 1.1). Of these two different types of uterine cancer, endometrial
cancer is more common, making up roughly 95% of all uterine cancer cases (92). In this
Dissertation (Chapter 3), I will investigate how a broader group of endometrial cancers
(UCEC), including endometrioid carcinoma and serous adenocarcinoma, differ from a
specific subtype, known as uterine carcinosarcoma UCS), in their gene expression
profiles and gene networks.
The most common endometrial cancers are endometrioid carcinosarcoma and
serous adenocarcinoma (5). Endometrioid carcinoma is the most common subtype (80%
of uterine cancer cases) and is also the only type I endometrial cancer. Type I endometrial
cancers are associated with an increase in estrogen (5,90), which can stem from obesity,
nulliparity, or a late onset of menopause,
among others (90,93). When detected in early
stages, as it usually is, endometrioid
carcinoma can be treated with surgery, and
therefore has a better prognosis than both
serous adenocarcinoma and uterine
carcinosarcoma (94). However, if an
endometrioid carcinoma goes untreated, it could
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Figure 1.1. Anatomical Structure of the
Uterus. Source: Shutterstock.

develop into a uterine carcinosarcoma though an epithelial-mesenchymal transition (5).
Endometrioid cancers have been associated with microsatellite instability (95), as well as
mutations in PTEN co-occurring with mutations in PIK3CA (96), PIK3R1 (97), or
ARID1A (5,93). Other implicated genes include KRAS (7), FGFR2 (98), and CTNNB1
(93).
Serous adenocarcinoma is the second most common endometrial cancer overall
(10% of endometrial cancer cases), and is the most common cancer of those that are type
II (5). Serous adenocarcinoma is most likely to arise from the atrophied endometrium in
post-menopausal women and usually is not detected until the later stages, leading to a
poorer diagnosis, a higher chance of recurrence, and a lower survival rate (5). Serous
adenocarcinoma, similar to endometrioid carcinoma, can also undergo an epithelial-tomesenchymal transition and become uterine carcinosarcomas (5). Serous
adenocarcinomas have also been shown to have similar genetic profiles of higher-grade
endometrioid carcinomas but are more likely to have copy number alterations compared
to their type I counterpart (7). Genes commonly associated with cases of serous
adenocarcinoma include TP53 (99), PIK3CA (99), and MYC (7).
Uterine carcinosarcoma (UCS) is a less frequent type II endometrial cancer, and
usually is not detected until it has become metastatic (6). Similar to serous
adenocarcinoma, prognosis and survival rates are worse compared to endometrioid
carcinoma (6). While they only make up 5% of all uterine cancers, the UCS subtype
contributes to of all 15% of uterine cancer deaths (6). UCSs are likely formed due to an
epithelial-to-mesenchymal transition from high-grade endometrioid cancers or serous
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adenocarcinomas. These tumors then transition into a uterine sarcoma phase in addition
to the existing endometrial cancer (5,95). This transition is enriched for uterine
carcinosarcoma initiation in particular compared to other cancer types and has been
associated with epigenetic changes in the promoters of microRNAs (100). While PTEN
mutations are common in endometrioid carcinomas and TP53 mutations are common in
serous adenocarcinomas, UCSs tend to have both mutations in both phases of the tumor
(100,101). In addition to these two genes, other genetic mutations shared between UCS
and UCEC include those in genes KRAS and PIK3CA (100). Genes specific to UCS have
also been identified and include RB1 (a tumor suppressor), U2AF1 (a splicing factor),
and ZBTB7B (a transcription factor) (100).
Uterine cancer most often originates in the endometrium due to an excess of
estrogen in the body to form endometrioid carcinomas. However, other cancers have also
been identified, like serous adenocarcinoma, which is usually caused by an atrophied
endometrium in post-menopausal women. While there are genetic differences between
these two cancers, both can develop a sarcoma phase by undergoing an epithelial to
mesenchymal transition and therefore becoming a UCS if left untreated. In this
Dissertation (Chapter 3), I will be investigating the gene expression similarities within
endometrioid and serous carcinomas (together known as UCEC) and comparing them to
that of UCSs to further analyze their respective genetic profiles, as well as the genetic
changes that take place.
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Biomarker Discovery Techniques
While ASD and endometrial cancer are two unrelated complex conditions, the
goal of this Dissertation was to use a variety of techniques, some overlapping, to uncover
useful biomarkers for each condition. Although biomarkers can take on many different
meanings in the field of science, as noted by Robert Califf (102), here they are interpreted
as an observable biological characteristic associated with a normal state, a disease, or a
disorder. These can include the expression level of an associated gene or the genotype of
an associated variant. One way to detect relevant biomarkers is through a network-based
approach. A network of biomarkers, such as a gene regulatory network, associated with a
specific condition has been shown to be better at disease prediction compared to single
genes, as well as better represent the heterogeneity of complex traits (103–105). The
genes within those networks and associated with those complex traits can then point to
implicated biological pathways (106). In this Dissertation, the polygenic biomarker
systems, or biosignatures, identified for ASD and endometrial cancer are based on DNA
and RNA patterns derived from several different genetic resources. These resources have
published their wet-lab experimental findings to allow scientists to integrate and
investigate using dry-lab tools and techniques, as done here.
A dataset published by the Simons Foundation Autism Research Initiative
(SFARI) and known as SPARK (Simons Foundation Powering Autism Research) was
used as a resource for genotypic and phenotypic information of ASD-affected individuals
and their families in this Dissertation. The SPARK dataset has phenotypic information
(including background history, a medical screening, and surveys regarding autistic traits
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and severity) available for 269,000 participants (including 106,000 ASD-affected),
47,000 of which have also submitted saliva for either whole-exome sequencing in
combination with genome-wide genotyping or whole-genome sequencing (22,000 ASDaffected) (107). The Simons Foundation hopes to recruit a total of 50,000 ASD-affected
individuals to identify variants common to this population (107). While they have yet to
reach their goal, the database has lent itself to gene (108,109) and variant (110)
discoveries in ASD-affected individuals.
One control group used for the ASD investigation was made up of individuals
from gnomAD (Genome Aggregation Database). gnomAD is a resource composed of
genomic information for almost 760 million variants from 76,000 unrelated participants
across ten populations (111). gnomAD has incorporated genomic data from over 50
programs and projects including 1000 Genomes, the Human Genome Diversity Project,
and the National Heart, Lung, and Blood Institute (111). The gnomAD genomic data used
for this project is freely available is summary information and based on population and
broad phenotypes. For example, in the ASD study described in this Dissertation, I was
able to extract summary information for a subset of Caucasian individuals that were
denoted as not having a neurological disease or disorder. Other studies have used
gnomAD to investigate variants associated with Menkes disease (112) and cancer (113),
as well as their association with other genetic features (114,115).
Another database composed of control individuals and used in this Dissertation is
the Genotype-Tissue Expression project (GTEx). GTEx set out in 2010 to establish a
database of tissue-specific expression information and identify variants that control the
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expression of associated genes in normal tissue known as expression quantitative trait
loci (eQTLs) (116,117). The availability of this baseline eQTL data can be used in the
search for DNA polymorphisms as an indicator of RNA expression control with variantgene-tissue associations in a disease-specific context. This is an important point because
an eQTL is a proxy for estimating RNA concentrations in specific tissue which is
impossible or unethical to directly sample for most human organs.
GTEx has published 4.2 million variant-gene associations, accomplished through
RNA sequencing of multiple tissue samples and DNA genotyping of blood samples for a
total of 838 post-mortem individuals (116,117). These sequencing and genotyping
resources, collected for the purpose of QTL discovery, are also available for analysis.
This database has been integral in a plethora of discoveries, including using tissue
samples to identify methylation patterns in the brain (118), using RNA-sequencing data
to investigate how altered DNA methylation profiles contribute to cancer (119), and
building tissue-specific gene co-expression and gene regulatory networks (120,121).
In this Dissertation, GTEx has been an invaluable resource. The loci associated
with the tissue-specific GTEx eQTLs served as our search space for investigating ASDassociated alleles. The DNA genotyping data was used as a control group for the ASD
analysis and the RNA-seq data allowed for investigation of the genes of interest for the
ASD analysis, as well as served as a control for the endometrial cancer analysis.
The Cancer Genome Atlas (TCGA) is a large database supported by the National
Cancer Institute that has focused on collecting and analyzing 20,000 normal and
cancerous samples across 33 cancer types (122). These samples underwent various forms
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of analysis, including DNA-sequencing, RNA-sequencing, microRNA-sequencing, DNA
genotyping, and DNA methylation sequencing (123). While the raw sequencing files are
protected, individual-specific and summarized processed data are freely available for
download (123). This resource has been used to investigate patterns and genes of interest
in specific cancer types, such as breast cancer (124), bladder cancer (125), as well as pancancer analyses (122,126). In this Dissertation, TCGA served as a resource for the
endometrial cancer study by providing RNA-seq data and sample metadata for
endometrioid and serous carcinomas (UCEC) as well as uterine carcinosarcomas (UCS).
The datasets described here have allowed for the identification of biomarkers using
differential gene expression and gene network-based techniques.
Differential expression (DE) analysis is an approach to investigate significant
increase or decrease in the levels of RNA or protein gene products when comparing two
conditions (127). DE genes can be identified with measurement techniques such as
microarrays or RNA-seq data followed by DE significance analysis implemented in
software programs like DESeq2, which uses negative binomial distributions to estimate
DE significance (128). Once differentially expressed genes are found to be associated
with a condition of interest, they can then be further explored by investigating their
corresponding regulatory mechanisms and biological pathways. While the cause of the
differential expression is important, the identification of those differentially expressed
genes is also relevant as they can act as potential future therapeutic targets (129). Gene
co-expression (i.e. correlation) levels can also be analyzed in a pair-wise approach within
the control and diseased states to build gene co-expression networks (130,131).
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Gene co-expression networks (GCNs) are another approach to investigate
differences in genic relationships, especially in complex diseases (132). Because
similarly expressed genes are often active in the same biological processes, changes in
those expression patterns can reflect condition-specific characteristics (130,132).
Therefore, the expression levels of gene pairs can be assessed in control and diseased
states to investigate changes in biological function. For example, two genes may tend to
rise and fall in their expression at the same time in cancer but have varied or unrelated
expression in control tissues. The two genes could then be analyzed for genetic mutations
specific to the cancerous samples and potential changes in cis-regulatory mechanisms
(130). This pairwise comparison can be completed for all genes of interest, and a network
made up of nodes (genes) and edges (lines between genes denoting co-expression) can be
built (130). GCNs have been founded for numerous conditions, including depression
(133), cancer (134), Alzheimer’s disease (135,136), and Parkinson’s disease (137). While
a GCN can stand alone, incorporation of regulation to form a gene regulatory network
(GRN) is one way to further investigate the observed changes in genic relationships
(127,132).
GRNs are another gene network class that incorporates cis- and trans-acting
transcriptional regulators of target genes via directed edges (138). These regulatory
elements can include transcription factors (TFs), TF binding sites, enhancers, and
promoters (138,139). GRNs are often tissue- or cell-type-specific, and can give more
context and insight into related complex diseases (139). This is important because these
regulatory elements are a likely culprit for the observed changes in gene co-expression
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patterns between diseased and control states (132). When implementing directed
regulatory edges into a GCN, the transcription factors can also be subjected to a
differential expression analysis to investigate if connected nodes are possibly
dysregulated due to changes in transcription factor expression (127). Gene regulatory
networks have been assembled for normal tissue (139), as well as other conditions,
processes, and diseases including cancer (140), drug metabolism (141), and hypertension
(142).
While GCNs rely on RNA profiles and GRNs incorporate target RNA and cis/trans-acting DNA regulatory elements, other DNA approaches can also be used to
identify biomarkers. Genome sequencing can identify changes in DNA related to a
diagnosis, like the ASD-associated mutations in SHANK proteins described earlier.
These genomic changes can include variations such as SNVs, insertions, and deletions,
and can be found using approaches like a genome-wide association study (GWAS) (143).
A GWAS surveys SNVs across two populations (usually cases and controls) to discover
DNA variants associated with a disease, condition, or disorder (144). These variants
associated with the phenotype of interest can then be further investigated or validated, as
was done in previous studies for Alzheimer’s disease (145), Crohn’s disease (146), and
schizophrenia (147).
In this Dissertation the discovered biomarkers were investigated using
computational approaches, including t-distributed stochastic neighbor embedding (tSNE), neural networks, and functional enrichment. t-SNE is an unsupervised
dimensionality reduction technique that allows for visualization of a large amount of data
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in a two dimensional space (148,149). The distribution of samples, represented by dots on
a scale-free plot, will reflect the similarities and differences in their features, so that
similar samples will cluster together (148). Therefore, the absolute location of each
sample in the plot will often change and is not as informative as its closest neighbors
(150). For better visualization, each sample in the plot can also be color-labeled based on
the characteristic or phenotype of interest (150). This technique has been used to
visualize genetic patterns in mutated cancer genes (150), microbiome data (151), and the
population structure of mosquitos (152). In this Dissertation, I will be using t-SNE to
visualize how the genotypic profiles of variants associated with ASD can better separate
ASD-affected and ASD-unaffected individuals, compared to random variants.
While t-SNE initially clusters samples based on their genetic information and then
labels them, neural networks can additionally use a supervised machine learning
approach to separate the groups of interest based on their labels and then identify features
that segregate with the phenotype (153,154). This is accomplished due to the inherent
structure of a neural network. First, the majority of samples (usually 70-80%) are used to
train an algorithm to identify the input features that can accurately distinguish between
the sample types (154). The features can be weighted higher or lower based on their
ability to classify samples correctly. Once trained, the algorithm is tested on the
remaining unlabeled data to see how well the network can accurately classify samples
based on the patterns of the weighted features (153). Neural networks have previously
used genetic data (such as SNP genotypes) as the input data to predict the presence or
absence of a complex disease (ranging from 50-90% accuracy) (155–157). As more
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research is completed and the number of small-effect loci associated with complex
diseases increases, the predictive power of these models will likely increase in tandem
(158). In this Dissertation, a neural network was used to compare the classification
accuracy of ASD-affected and ASD-unaffected individuals into their respective groups
based on their genotypes at significant and random variants.
For the uterine cancer project in this Dissertation, one way the GCN and GRN
biomarkers were validated was through functional enrichment. A functional enrichment
analysis compares a gene set of interest with thousands of annotated gene lists associated
with biological processes, pathways, and phenotypes, among other features (159,160). If
the input gene list has a significant amount of overlap with one of the annotated lists
relative to the genome background, then the gene list would be considered functionally
enriched for that function or process (159). In this Dissertation, the ToppFun resource in
the ToppGene suite was used to investigate annotations associated with discovered
biomarkers in the cancer-specific GCNs and GRNs (160). The significant annotations
then reveal potential processes or pathways affected in the cancer cells. This approach
has also been used to investigate functional associations for atrial fibrillation (161),
skeletal muscle atrophy (162), and osteoarthritis.

Dissertation Outline, Novel Contributions, and Broader Impacts
During my time at Clemson, I have discovered and further investigated
biomarkers associated with ASD and uterine cancer. This was accomplished by
integrating genetic and transcriptomic data from multiple resources, distinguishing varied
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patterns between groups of interest using bioinformatic techniques, and further validating
them via classification and enrichment tools. Chapter 2 discusses an eQTL-based study
from which variants with significantly different allele distributions between ASDaffected and ASD-unaffected individuals were discovered. The classification potential of
the variants was explored using t-SNE and a neural network, while their corresponding
genes were investigated for annotated brain associations. The ASD eQTL biomarker
study is important as it supports the growing evidence that the accumulation of common
regulatory variants can potentially play a role in the development of ASD. Chapter 3
describes the construction and analysis of condition-specific GCNs and their potential
regulatory relationships for normal uterine tissue, UCEC, and UCS. These networks
underwent differential expression analysis and functional enrichment, which allowed for
a more comprehensive look into the biological functions affected in uterine cancer and
provided more context compared to previous singular gene analyses. This study can be
incorporated into existing knowledge surrounding the genetics of uterine cancer and
demonstrates future potential to become a tool for a more specialized prognosis and
treatment. Chapter 4 completes the dissertation with a summary of my findings and
contributions.
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CHAPTER TWO
DISCOVERY OF EQTL ALLELES ASSOCIATED WITH AUTISM SPECTRUM
DISORDER
Note: This chapter is currently under review as a manuscript entitled “Discovery of
eQTL Alleles Associated with Autism Spectrum Disorder: A Case-Control Study” by
Allison R Hickman, Benafsh Husain, Bradley Selee, Rini Pauly, Yuqing Hang, and F
Alex Feltus for publication in Journal of Autism and Developmental Disorders.

Abstract
Autism Spectrum Disorder (ASD) is a heterogenous neurodevelopmental disorder
characterized by challenges in social communication as well as repetitive or restrictive
behaviors. Many large-scale genetic changes have been associated with ASD including
mutations in genes SHANK3 and MECP2 and copy number variations in regions 15q1113 and 16p11.2. However, these genetic associations among others can only be identified
in roughly 20% of the autistic population. The aggregation of risk alleles at common
variants have also been shown to contribute to ASD emergence. In this study, we
searched for eQTL-associated variants with significantly different allele distributions
between ASD-affected and control individuals using a Fisher’s Exact Test and assessed
their classification potential on separate ASD-affected and control individuals using an
artificial neural network and tSNE. When using general population control datasets
(gnomAD and GTEx), 30 significant variants (associated with 174 tissue-specific eQTLs)
were identified. When assessed for their classification potential, these markers were able
to classify individuals into their correct groups with a 90-100% accuracy. Several
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significant variants fell within brain-specific regulatory regions or had been associated
with a significant change in gene expression in a brain tissue. Additionally, two genes
associated with the significant variants, CARNS1 and CIDEA, had previously been
identified as differentially expressed in brains of ASD-affected individuals. This study
was only able to assess the variants available in the SPARK, GTEx, and gnomAD
datasets. Because the genotyping of SPARK was centered in and around genes, more
variants in intragenic regions remain to be investigated. In addition, we only surveyed
ASD-affected individuals with ASD-unaffected parents to remove those with inherited
large-scale genetic changes. This may have limited the statistical power and variant
discovery within the study and should be investigated in the future. eQTLs are an avenue
in which a DNA variant can result in tissue-specific changes in gene expression across
brain and non-brain tissues. Further research will be needed to validate if the eQTLs
discovered can result in the myriad of brain and non-brain phenotypic traits seen in ASDaffected individuals.
Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder caused by a
combination of genetic and environmental factors resulting in a range of various
phenotypes across ASD-affected individuals (163). The US Center for Disease Control
estimates that 1 in every 54 people have ASD with more males affected than females at a
3:1 ratio (164,165). While ASD can be diagnosed as early as two years of age, diagnosis
usually occurs around the age of four (166). Subtraits, including repetitive behavior,
challenges in social settings, and sensory issues, will vary among ASD-affected
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individuals in their presentation and in severity (163). Comorbidities that occur with ASD
can include brain-based conditions, such as epilepsy or anxiety, as well as non-brainbased conditions, such as inflammatory bowel disease and cardiac dysrhythmia
(4,167,168). Environmental risks can include increased paternal age, birth trauma, and
caesarean section delivery (169,170). In addition to environmental risks, many molecular
variations have been associated with ASD.
Complex human phenotypes involve allelic variation across multiple genes
(171,172). ASD is clearly a complex trait where as many as 1,000 genes have been
associated with the phenotype in the Simons Foundation Autism Research Initiative
(SFARI) Gene database (173). Genomic features ranging in size from large DNA copy
number variants (CNV) to single nucleotide variants (SNV) have been associated with
ASD (163,174,175). CNVs, large-scale duplications or deletions, have an impact on
gene dosage and can result in haploinsufficiency or altered transcription patterns (176).
Present in up to 10% of ASD-affected individuals, CNVs have been associated with
genes SHANK2, SYNGAP1, DLGAP2, and others (50). These can also occur in large
chromosomal regions, such as 15q11-13, 16p11.2, and 22q11.2 (44,174). Single gene
mutations have also been identified, some of which as a result of a comorbidity, such as
FMR1 for fragile X syndrome and MECP2 for Rett syndrome (177). For idiopathic cases,
mutations have been identified in genes associated with synapsis, like neuroligins
(NLGN3, NLGN4), shank proteins (SHANK2, SHANK3), and neurexins (CTNAP2,
NRXN1) (178–182). However, among these associations and others, no single
association accounts for more than 2% of all cases (183). It is possible that for most
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ASD-affected individuals, the cause is more likely to be a network of altered genetic
interactions rather than singular change with a global effect.
In addition to allelic variation in gene dosage and protein coding regions, it is
likely that many human traits are modulated by genetic variation in gene expression in
gene regulatory networks (GRNs) (184). One technique to detect variation in gene output
is through expression quantitative trait locus (eQTL) analysis by which a DNA variant at
a specific genomic position is shown to influence the RNA expression level of a gene in a
tissue-specific context (185). eQTLs are identified through genome sequencing and
transcriptome analysis, via microarray or RNA-seq, where RNA expression levels of
each gene is tested for association with DNA polymorphisms across individuals in a
defined DNA window surrounding the locus (186). eQTLs afford a better understanding
of natural variation and disease by offering a mechanistic explanation for variant alleles
that segregate with a phenotype. With the publication of normal human tissue-specific
eQTLs, such as those described by the Genotype-Tissue Expression (GTEx) project
(187), one can generate tissue-specific gene expression hypotheses using genotype calls
in affected and unaffected groups without the need of destructive sampling of human
tissue.
eQTLs have previously been employed in ASD research. Sun et. al. combined
ASD GWAS SNV genotypes with frontal cortex RNA gene expression to identify eQTLs
with altered expression levels across 76 genes between ASD-affected and control
individuals (188). Most eQTLs were found to influence regulation due to their overlap
with histone marks or an association with the methylation level of each associated gene.
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Other studies have uncovered multiple variants associated with expression levels of a
particular gene. LoParo and Waldman looked exclusively at the oxytocin receptor gene
(OXTR) and found four SNVs (3 intronic and 1 in the promoter) in which an allele was
associated with a higher risk of ASD (189). Wu et. al. found three significant SNVs
associated with ASD in the transcription start site of the MEGF10 gene, which is thought
to be active in modulating neural connections during development (190).
By expanding polymorphism searches into intergenic genomic regions through
whole genome sequencing as opposed to exome sequencing, there are likely to be many
genotype-phenotype associations to uncover that function at the level of gene expression
control. However, because of this widened scope, new techniques including machine
learning may be necessary for the detection of genetic associations with ASD. Artificial
neural networks (ANNs) are a machine learning technique used to detect patterns in an
input of features (e.g. histology images, gene expression profiles, clinical data) capable of
classifying labeled groups (191). Deep learning ANNs, especially the Multi-Layer
Perceptron (MLP) model, have been shown to be more effective in predicting disease
compared to other traditional methods such as logistic regression models (192). MLPs
were first used in 2001 to distinguish an individual’s specific type of small, round blue
cell tumor based on their gene expression profile (193). Because the initial application of
ANNs in image analysis (194), it is not surprising that a large majority of ASD-related
machine learning studies have been completed on brain imaging data (195,196). A
valuable resource used in a lot of these studies is the ASD brain imaging data exchange
database, which contains structural and functional imaging data from over 500
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individuals with ASD and roughly the same number of controls (197). With these data,
these projects tend to have a classification accuracy around 70-90% (195).
There are fewer studies that have used DNA sequence patterns as input to
machine learning methods. Jiao et. al. used the genotypes of 29 SNVs to predict
symptom severity (mild, moderate, severe) among ASD-affected individuals (198). The
SNVs fell within the introns, exons, promoter, or UTRs of nine genes that had previously
been associated with ASD subtraits, and the corresponding model was able to accurately
predict the symptom severity in 67% of individuals (198). Another study used machine
learning to measure the impact of a variant on splicing patterns (199). That study used an
ANN to identify DNA variants between individuals with and without ASD. Although the
number of variants between the two groups did not significantly differ, the variants
within the ASD-affected individuals were associated with more brain-expressed genes
compared to controls, particularly those related to brain development and function (199).
One driver of genetic discovery for ASD and other phenotypes are large databases
filled with genotyped individuals who are often tagged with rich phenotype data. The
Simons Foundation Powering Autism Research (SPARK) dataset published by SFARI
contains genomic and phenotypic information for 27,615 individuals, consisting of 9,779
ASD-affected individuals and their immediate family members (107). The genomic data
for each individual includes exome and whole genome genotyping performed on a saliva
sample, while the phenotypic data includes an individual’s background history, a basic
medical screening, a developmental coordination disorder questionnaire, a repetitive
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behavior questionnaire, and a social communication questionnaire (107). This dataset has
allowed for new insights and discoveries in the field of ASD research (200–202).
Other genotype databases contain huge numbers of genotyped individuals that
serve to estimate allele frequencies and can be used to control for confounding population
structure based on known ancestry. The Genome Aggregation Database (gnomAD) is a
resource of genetic information spanning 105 million indels and 602 million SNVs
produced by whole genome sequencing of 71,702 individuals (111). Over 52 projects
have contributed to this dataset including the 1000 Genomes Project (203) and GTEx
(187). While gnomAD has published genotype summary information for many
populations, GTEx has completed whole genome sequencing for 818 Caucasian and
African American individuals (phs000424.v8.p2) and contains individual-specific
genotyping information available for analysis. Together, the gnomAD and GTEx
datasets contain both population-specific and individual-specific genotype data to
compare with populations of interest, like those of ASD-affected individuals (204,205).
Another goal for GTEx was to publish tissue-specific gene expression data in
relation to cis-regulation variants. In the eighth version of the database, there are 17,382
tissue samples, 15,201 of which underwent expression quantitative trail loci (eQTL)
analysis. While GTEx investigated tissues from major human organs, PsychENCODE is
a genomics database that focuses solely on brain features (206). These derived brainspecific lists include enhancers specific to the pre-frontal cortex, acetylation peaks
specific to the pre-frontal cortex, temporal cortex, and cerebellar cortex, active brain
eQTLs, and differential gene expression results comparing ASD-affected individuals to
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controls (206). These gene regulation data available through GTEx and PsychENCODE
have been used to further investigate ASD (207–209). Chau and colleagues used the
BrainSpan RNA-seq dataset published by PsychENCODE to find that loss-of-function
mutations were present in isoforms and were expressed at higher levels in ASD-affected
individuals prenatally compared to controls (206,207). Others used information from
GTEx, along with other datasets, to identify 14 differentially expressed genes in ASD and
to find common trends in pathways and functions among ASD genes (208,209).
Many large effect genetic associations have been identified in ASD-affected
individuals, such as the genes SHANK3 and MECP2 as well as the CNV regions 15q11.2
and 16p11.2 (173). However, these large effects can only be identified in roughly 20% of
the ASD population (4). It is possible that for most ASD-affected individuals, the
disorder stems from the accumulation of many small effect changes (34). eQTLs are one
small effect genetic feature that has not been fully investigated on a genome-wide scale in
relation to ASD. In this study, we used eQTLs detected in any tissue as our search space
for genetic associations with ASD. While some studies have investigated eQTLs
surrounding specific genes, we have not limited our search to genes already associated
with the brain or with ASD (189,190). After discovering eQTL alleles associated with
ASD, we employ machine learning models to test their classification accuracy.
Results
In this study we were interested in finding alleles associated with ASD at eQTL
loci. An overview of the workflow can be seen in Figure 2.1. All tissue-specific eQTLs
were downloaded from GTEx (N = 1,207,976 eQTLs), however only those that met the
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significance threshold recommended by GTEx (qval < 0.05) were retained for further
analysis (Table 2.1). Of the 475,829 eQTLs that met the significance threshold, 98,934
were associated with a brain tissue (Table 2.1). The variants associated with the 475,829
eQTLs were extracted and used for the following analysis.
The primary analysis was organized into a Discovery stage and a Classification
stage. In the Discovery stage, variants with significantly different allelic distributions
between ASD-affected and ASD-unaffected individuals were identified. In the
Classification stage, tSNE and a neural network were used to observe the classification of
ASD-affected and ASD-unaffected individuals into their respective groups based on the
genotype profiles at the significant variants. The Discovery stage was composed of two
experiments: investigating the SPARK and GTEx datasets, as well as the SPARK and
gnomAD datasets. The SPARK dataset was made up of randomly selected 360 ASDaffected individuals, while GTEx and gnomAD had 360 and 37,543 ASD-unaffected
individuals, respectively. For the SPARK and GTEx Classification datasets the 360
individuals were chosen at random, and only one member of each family was chosen to
avoid familial substructures. In the gnomAD dataset, no individual-specific data was
available, so the population-specific genetic data for each variant was used.
Once the experimental and control groups were determined, the variants from the
GTEx eQTLs were compared to the genomic information available in each control
dataset. For the SPARK and GTEx datasets, variants had to have genotype calls for at
least 90% of the Discovery individuals to be considered for further analysis. The
SPARK-gnomAD experiment was able to investigate 12,933 eQTL-associated variants,
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while the SPARK-GTEx experiment investigated 12,789 eQTL-associated variants
(Table 2.1).

Figure 2.1: ASD Allele Discovery Workflow.
This study was broken into two stages: Discovery and Classification. In the Discovery stage, two
experiments were conducted to investigate variants with significantly different allele distributions between
ASD-affected and ASD-unaffected individuals at eQTL loci: a SPARK-GTEx experiment and a SPARKgnomAD experiment. At each eQTL associated variant, a Fisher’s Exact Test was performed to obtain two
separate lists of variants of interest (34 for the SPARK-GTEx experiment and 83 for the SPARK-gnomAD
experiment). The variants found in both lists make up the final list of 30 significant variants that were
associated with 174 tissue-specific eQTLs. To investigate how well the 30 significant variants could

30

classify ASD-affected and ASD-unaffected individuals the Classification stage used tSNE and neural
networks on existing and new subsets of individuals.

Table 2.1. eQTL Analysis Summary
Total
eQTLs:
Brain eQTLs: Variants Significant Significant
eQTLs
GTEx qval GTEx qval<
Tested
Variants
eQTLs
< 0.05
0.05
SPARK12933
83
300
gnomAD
475829
98934
SPARK-GTEx 1207976
12789
34
182
Consensus
12789
30
174

Significant
eQTLs in
Brain

For each experiment, every variant underwent a Fisher’s Exact Test to compare
the number of reference and alternate alleles between the ASD-affected and ASDunaffected individuals. The variants were then ranked by their p-values from lowest to
highest. As each variant represents a single hypothesis, we corrected for false discovery
using the Benjamini-Hochberg procedure and a false discovery rate of 1%. For each
variant, the critical value was calculated (critical value = (rank/total number of variants) *
0.01). We then moved down the ranked variant list to find the last variant where the pvalue was less than the critical value. The variant information (including the reference
allele counts, alternate allele counts, ranks, p-values and critical values) for the SPARKGTEx experiment and SPARK-gnomAD experiment is also available (Supplemental
Table 2.1 and Supplemental Table 2.2)
The 34 significant variants discovered in the SPARK-GTEx experiment were then
compared to the 83 significant variants from the SPARK-gnomAD experiment. There
were 30 variants that were found to be significant among both experiments
(Supplemental Table 2.3). These were deemed to be the significant variants. These
significant variants were then compared to the 475,829 GTEx eQTLs (with a q-val <
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52
27
27

0.05) to find their gene and tissue associations. The significant variants aligned with a
total of 174 tissue-specific eQTLs (Table 2.1, Supplemental Table 2.4), representing 34
genes and 49 tissues. The 174 associated eQTLs were then referred to as “significant
eQTLs”, and the 34 associated genes as significant genes. The significant genes and their
tissue associations can be seen in Table 2.2. The expression levels of the significant

genes across multiple brain tissues can be seen in Figure 2.2. An eQTL summary by
tissue can be seen in Supplemental Table 2.5.
Figure 2.2: Heatmap Depicting Gene Expression of Significant Genes in Brain Tissues.
Expression values of the significant genes were derived from brain samples of the GTEx dataset were put
into a matrix and normalized. The darkly colored blocks at the top of the figure represent the brain region
from which the sample was taken and genes were sorted by hierarchical clustering. In the heatmap red
represent higher levels of expression, while blue represents lower levels of expression. For example, ANO5
and KLRC3 had lower levels of expression in the cerebellum and cerebellar hemisphere compared to other
tissues.

We were interested in any brain known associations among the significant eQTLs.
PsychENCODE has published a list of active brain enhancers, lists of acetylation peaks
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specific to the pre-frontal cortex (PFC), cerebellar cortex (CBC), and temporal cortex
(TC) areas of the brain, a list of active brain eQTLs, and a list of genes differentially
expressed in ASD (206). These associations were downloaded and compared to the list of
significant variants and significant genes. Fourteen of the significant genes had an
association of interest (Table 2.3). They were associated with a variant that fell within a
brain regulatory region or were associated with a brain or endocrine tissue through GTEx.
To further investigate the classification accuracy of the genotype profiles of the
significant variants, we used tSNE and a MLP neural network in the Classification stage
of the study. The Classification stage consisted of three subsets of individuals: the
Caucasian subset used in the Discovery stage, a new African American subset, and a new
Caucasian subset. For this stage all the ASD-affected individuals came from the SPARK
dataset while all the ASD-unaffected individuals came from the GTEx dataset. The
Discovery Caucasian subset was made up of the same 360 individuals used earlier (180
ASD-unaffected females, 180 ASD-unaffected males, 180 ASD-affected females, 180
ASD-affected males), while the African American Classification subset (8 ASDunaffected females, 40 ASD-unaffected males, 8 ASD-affected females, 40 ASD-affected
males) and the Caucasian Classification subset (60 ASD-unaffected females, 60 ASDunaffected males, 60 ASD-affected females, 60 ASD-affected males) introduced new
individuals.
First, tSNE was used to visualize how individuals from the Caucasian Discovery
subset segregated based on their genotypic profiles at the significant variants and all
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variants tested. In Figure 2.3A, the genotype profiles at the significant variants were able
to segregate ASD-affected (blue dots) and ASD-unaffected individuals (orange dots)

Figure 2.3: tSNE of the Discovery
Subset at All Tested eQTL
Variants and Significant Variants.
tSNE allows for the visualization and
distribution of individuals in the
Caucasian Discovery subset based on
their genotype profiles at the
significant variants found in the
Discovery stage of this study (N=30,
panels A and B) and all variants
tested (N=12,789, panels C and D).
In these tSNE plots, each dot
represents an individual. In plots A
and C the individuals were colored
based on their ASD status, while in
plots B and D, individuals were
colored based on sex.

apart from a few GTEx outliers that clustered with the SPARK individuals. However, this
was not true when considering the genotype profiles at all variants we tested, seen in
Figure 2.3C. To ensure that the individuals were not segregating by sex, sex labels were
used in plots Figure 2.3B and 2.3D: males (green dots) and females (purple dots). In
Figure 2.3B, there are no distinguishable clusters based on sex, which showed that the
two main clusters in Figure 2.3A were not sex related. In addition to sex labels, labels
based on ASD severity can be found in Supplemental Figure 2.1. We observed that when
reducing the number of variants to only those found to be significant, tSNE was able to
separate individuals based on their genotype profiles and therefore their ASD status.
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Table 2.2. Significant Genes and their Tissue Associations
Gene Name

Tissue

ACADVL

Adipose Subcutaneous, Adipose Visceral Omentum, Artery Aorta, Artery Tibial, Colon Sigmoid, Esophagus
Gastroesophageal Junction, Nerve Tibial, Testis, Whole Blood
Artery Aorta, Artery Tibial, Lung, Ovary,
Heart Left Ventricle
Artery Tibial, Colon Sigmoid, Colon Transverse, Pituitary, Skin Not Sun Exposed Suprapubic, Skin Sun Exposed
Lower leg, Stomach
Heart Left Ventricle
Adrenal Gland, Artery Aorta, Artery Tibial, Brain Amygdala, Brain Anterior cingulate cortex BA24, Brain
Caudate basal ganglia, Brain Cerebellar Hemisphere, Brain Cerebellum, Brain Cortex, Brain Frontal Cortex
BA9, Brain Hippocampus, Brain Hypothalamus, Brain Nucleus accumbens basal ganglia, Brain Putamen basal
ganglia, Brain Spinal cord cervical c-1, Brain Substantia nigra, Cells Cultured fibroblasts, Colon Sigmoid, Colon
Transverse, Esophagus Gastroesophageal Junction, Esophagus Mucosa, Esophagus Muscularis, Heart Atrial
Appendage, Minor Salivary Gland, Nerve Tibial, Ovary, Pancreas, Pituitary, Prostate, Skin Not Sun Exposed
Suprapubic, Skin Sun Exposed Lower leg, Spleen, Stomach, Testis, Thyroid, Uterus, Vagina
Adrenal Gland, Artery Aorta, Artery Coronary, Artery Tibial, Breast Mammary Tissue, Colon Sigmoid, Colon
Transverse, Esophagus Gastroesophageal Junction, Esophagus Mucosa, Esophagus Muscularis, Heart Atrial
Appendage, Lung, Minor Salivary Gland, Ovary, Prostate, Stomach, Testis, Thyroid, Uterus, Whole Blood
Esophagus Mucosa
Skin Sun Exposed Lower leg
Liver
Cells Cultured fibroblasts, Lung, Spleen, Thyroid,
Lung, Spleen, Whole Blood
Adipose Subcutaneous, Esophagus Gastroesophageal Junction
Lung
Skin Sun Exposed Lower leg
Nerve Tibial
Adipose Subcutaneous, Adipose Visceral Omentum, Adrenal Gland, Artery Aorta, Artery Tibial, Brain Anterior
cingulate cortex BA24, Brain Caudate basal ganglia, Brain Cortex, Brain Hippocampus, Brain Putamen basal
ganglia, Brain Spinal cord cervical c-1, Cells Cultured fibroblasts, Cells EBV-transformed lymphocytes, Colon
Sigmoid, Colon Transverse, Esophagus Gastroesophageal Junction, Esophagus Mucosa, Esophagus Muscularis,
Heart Left Ventricle, Kidney Cortex, Lung, Minor Salivary Gland, Muscle Skeletal, Nerve Tibial, Pancreas,
Pituitary, Prostate, Skin Not Sun Exposed Suprapubic, Skin Sun Exposed Lower leg, Small Intestine Terminal
Ileum, Spleen, Stomach, Testis, Thyroid, Vagina, Whole Blood
Kidney Cortex
Testis
Thyroid
Brain Putamen basal ganglia, Cells EBV-transformed lymphocytes
Esophagus Mucosa
Nerve Tibial
Adipose Subcutaneous, Breast Mammary Tissue, Esophagus Gastroesophageal Junction

ANO5
ASIC1
BET1L
CARNS1
CES1

CES1P1

CIDEA
CNTN2
CRELD2
GBA
KLRC3
KLRC4
KRTAP5-9
LCE4A
LINC02102
MAN2C1

NQO2
PAPOLB
PMPCB
POLR1B
POM121B
PTGIS
RP11817O13.8
SIRPB1

SLC5A10
SNORD3B-2
SPATA31C1
SYT5
TTL
VARS2

Brain Anterior cingulate cortex BA24, Brain Caudate basal ganglia, Brain Cortex, Brain Nucleus accumbens
basal ganglia, Breast Mammary Tissue, Cells Cultured fibroblasts, Cells EBV-transformed lymphocytes, Heart
Atrial Appendage, Pituitary
Testis
Adipose Subcutaneous
Brain Cortex, Pituitary
Brain Caudate basal ganglia, Brain Putamen basal ganglia
Esophagus Gastroesophageal Junction, Skin Not Sun Exposed Suprapubic
Cells Cultured fibroblasts, Cells EBV-transformed lymphocytes, Colon Transverse, Heart Left Ventricle, Skin
Sun Exposed Lower leg, Spleen, Whole Blood
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XXbacBPG181B23.7
ZNF490
ZNF587B

Vagina
Adipose Subcutaneous, Artery Aorta, Artery Tibial, Breast Mammary Tissue, Esophagus Gastroesophageal
Junction, Esophagus Muscularis, Nerve Tibial, Whole Blood
Colon Sigmoid
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Table 2.3. Significant Genes with at least 1 Brain Association
Gene Name

Brain/Endocrine Association

ACADVL
ANO5
BET1L
CARNS1
CES1
CES1P1
CIDEA
KLRC3
KLRC4
MAN2C1
POLR1B

Associated Variant within CBC Acetylation Peak
Associated Variant within PFC Acetylation Peak and TC Acetylation Peak
eQTL Association with Pituitary Gland
PsychENCODE ASD DEG; lower in ASD
eQTL Associations with 13 Brain Tissues, Adrenal Gland, and Pituitary Gland
eQTL Association with Adrenal Gland
PsychENCODE ASD DEG; lower in ASD
Associated Variant in PFC Acetylation Peak and TC Acetylation Peak
Associated Variant in PFC Acetylation Peak and TC Acetylation Peak
eQTL Associations with Adrenal Gland, 6 Brain Tissues, and Pituitary Gland
Associated Variant within PFC Acetylation Peak, TC Acetylation Peak, and CBC
Acetylation Peak; eQTL Assocation with Brain Putamen Basal Ganglia

SIRPB1

Associated Variant within PsychENCODE Enhancer and Gene/Variant Assocation with
PsychENCODE eQTL; eQTL Association with 4 Brain Tissues and Pituitary Gland

SPATA31C1
SYT5

eQTL Associations with Brain Cortex and Pituitary Gland
eQTL Associations with Brain Putamen and Caudate Basal Ganglia

The tSNE approach employed above was used similarly for the African American
and Caucasian Classification subsets. In Figure 2.4 the distribution of individuals based
on the genotype profiles at the 30 significant variants and 30 random variants can be
seen. For both populations the genotype profiles at the significant variants (Figure 2.4A
and 2.4B) were able to separate ASD-affected and ASD-unaffected individuals better
than the same number of random variants (Figure 2.4C and 2.4D). The separation of
African American ASD-affected and ASD-unaffected individuals in Figure 2.4B was not
as distinct as the Caucasian individuals in Figure 2.4A. This could possibly be attributed
to the lesser number of African American individuals available within the SPARK
dataset. The matrices used to create the tSNE plots in Figure 2.3 and Figure 2.4 were

also used with a MLP neural network to observe how well it could classify individuals
into ASD-affected and ASD-unaffected groups based on their genotype profiles at
relevant loci (Figure 2.5). Across all three groups of individuals (Caucasian Discovery,
Caucasian Classification, and African American Classification) the classification
accuracy based on the genotype profiles of the 30 significant variants was higher (ranging
from 90% to 100%) than that of 30 random variants or all variants tested (accuracy
ranging from 30% to 70%). The random and complete variant lists also have more
sporadic fluctuations in accuracy. Nonetheless, their average classification accuracy
centered around 50%, which is expected for a random classification into two groups.

Figure 2.4: tSNE of Caucasian and African American Classification Subsets at Significant and
Random Variants.
Using tSNE the distribution of Caucasian and African American Classification subsets can be seen when
using the genotype profiles of the 30 significant variants as input (panels A and B), compared to using that

38

of 30 random variants (panels C and D). Each dot represents an individual, and the color of each dot
represents that individual’s ASD status.

Finally, we tested if the significant variants found using GTEx and gnomAD as

control datasets would also be discovered if we used ASD-unaffected siblings from the
SPARK dataset as the control. This is referred to as the secondary analysis in this study,
an overview of which can be seen in Figure 2.6. The same Caucasian Discovery subset
was used in conjunction with 360 ASD-unaffected siblings from the SPARK dataset (180
ASD-unaffected males, 180 ASD- unaffected females). While these ASD-unaffected
controls were siblings of ASD-affected probands, there were enough individuals within
the dataset to ensure that there were no familial relations within or between the ASDaffected and ASD-unaffected groups. The same approach was taken for this experiment
as the initial Discovery stage of the study. For each variant investigated, 90% of
individuals from the SPARK ASD-affected and SPARK ASD-unaffected subsets had to
have a genotype call. A Fisher’s Exact Test was used at each variant to compare the
allelic distributions of the ASD-affected and ASD-unaffected groups. The variants were
ranked based on their p-value, and a Benjamini-Hochberg correction was applied.
Between these two groups, no significant variants were discovered after BenjaminiHochberg correction. A tSNE plot was used to compare the segregation of SPARK ASDaffected, SPARK ASD-unaffected, and GTEx ASD-unaffected individuals at the 30
significant variants found in the earlier experiments (Figure 2.6). The plot shows all
SPARK individuals clustering together, while the GTEx ASD-unaffected individuals
segregate separately except for two individuals (seen as two blue dots among the yellow
and green).
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Figure 2.5: Neural Network Classification Accuracy for Various Datasets over 1000 Epochs.
A MLP neural network was used to observe how individuals could be classified into ASD-affected and
ASD-unaffected groups using their genotype profiles across different data inputs. Within all three subsets
of individuals (Caucasian Discovery subset, Caucasian Classification subset, and African American
Classification subset) using the genotype profiles of the 30 significant variants classified individuals at a
higher accuracy compared to random variants (N=30) and all variants tested (N = 12,789).

Figure 2.6: Analysis Investigating Allelic Distributions between
SPARK ASD-Affected Individuals and Unrelated SPARK ASD-Unaffected Individuals.
We investigated if the significant variants found in the initial Discovery stage of this analysis carried over
when comparing SPARK ASD-affected individuals to unrelated ASD-unaffected individuals with ASDaffected siblings. When using a Fisher’s Exact Test to analyze the allelic distributions at eQTL variants, no
variants had a significantly different distribution between the ASD-affected and ASD-unaffected subsets. A
tSNE plot was then used to visualize the distribution of Caucasian SPARK ASD-affected individuals,
Caucasian SPARK ASD-unaffected individuals, and GTEx ASD-unaffected individuals at the previously
identified significant variants.
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Discussion
In this study, we set out to identify variants at eQTL-associated loci with
significantly different allele distributions between ASD-affected and ASD-unaffected
individuals. Using controls from non-ASD datasets, 30 significant variants associated
with 34 genes were identified. Interestingly, when using unrelated ASD-unaffected
siblings of ASD-affected individuals, no variants had significantly different allele
distributions. When visualizing the distribution of ASD-affected and ASD-unaffected
individuals from the Caucasian Discovery subset, Caucasian Classification subset, and
African American Classification subset in Figure 2.3 and Figure 2.4, ASD-affected and
ASD-unaffected individuals were seen to easily segregate based on their genotype
profiles at the 30 significant variants identified in the Discovery stage. It is unlikely that
the ASD-affected and ASD-unaffected groups are separating based on any possible
dataset bias. In Figure 2.3A, several GTEx ASD-unaffected individuals (blue dots)
separated with the SPARK ASD-affected individuals (orange dots) when analyzing the
genotype profiles from the significant variants. If there were ascertainment bias (210), we
would expect to see separation of the datasets in Figure 2.3C, Figure 2.4C, and Figure
2.4D as well when observing the distribution of individuals at all variants tested or 30
random variants. It is possible that the few GTEx ASD-unaffected individuals that
separated with the ASD-affected SPARK individuals (seen in Figure 2.3, Figure 2.4,
Figure 2.6, and Supplemental Figure 2.1) have ASD-affected relatives. That information
was not included in the phenotypic surveys for the GTEx dataset but could be examined
in future studies.
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Another interesting characteristic found in several of the tSNE plots was the
formation of clusters within the ASD-affected and ASD-related groups at significant
variants. In Figure 2.3, Figure 2.6, and Supplemental Figure 2.1 there are three subclusters when observing individuals from the SPARK dataset. We tested to see if this
sub-cluster formation was due to gender (Figure 2.3B) or to ASD severity (Additional
File 1: Supplemental Figure 1), however neither trait segregated with the clusters. These
clusters were also not distinctly present in Figure 2.3C (when observing all variants) or
Figure 2.4 (when using the Discovery subsets). Because they were not present when
using genotype profiles at all variants, it is likely something specific about these
significant 30 variants that results in the formation of the sub-clusters. They were not
seen in Figure 2.4, but it is possible this was because of the fewer number of individuals
in the Classification subsets, as there were 120 Caucasian ASD-affected individuals and
48 African American ASD-affected individuals in the Classification subsets, compared to
360 individuals in the Discovery subset. This is reinforced by the slight cluster formation
seen in Supplemental Figure 2.1, which contained 90 less severe ASD-affected
individuals and 90 more severe ASD-affected individuals. Therefore, the sub-cluster
formation among ASD-affected individuals at the significant variants seems to become
more distinct as the number of individuals increases. This is typical of tSNE
visualization, where the patterns become clearer as the number of individuals increases.
The sub-cluster formation at the significant variants can also be seen when SPARK ASDrelated individuals were added in. In Figure 2.6, the ASD-related individuals are
segregating into sub-clusters along with the ASD-affected individuals, while the GTEx
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ASD-unaffected individuals do not. We hope to further investigate any other possible
associations with these sub-clusters in future studies.
The datasets that underwent tSNE visualization were also subject to a neural
network analysis where a machine learning model predicted if an individual was ASDaffected or ASD-unaffected based on their genotype profile. The model was able to
classify individuals with a high accuracy when inputting the genotypes for the significant
variants for all three groups tested: Caucasian Discovery subset, Caucasian Classification
subset, and African American Classification subset. When using the genotypes for all
variants or random variants, the classification accuracy was much lower, fluctuating
between 30-70%. For these results, the neural network predictions seem to become more
stable as more individuals are added. For example, the Caucasian Discovery subset has
the most individuals (720 total) and the most consistent trends in the classification
accuracy, while the African American Classification subset has the least individuals (96
total) and the least consistency in classification accuracy when using genotypes at 30
random variants as input.
In the secondary analysis all variants were tested to find those that had
significantly different allele distributions between SPARK ASD-affected and SPARK
ASD-unaffected individuals, but no variants were identified as significant. To visualize
this, a tSNE plot was used for the genotype profiles at the significant variants of the
primary analysis for 360 SPARK ASD-affected, 360 SPARK ASD-unaffected, and 360
GTEx ASD-unaffected individuals. In Figure 2.6, the SPARK ASD-unaffected
individuals can be seen segregating with the SPARK ASD-affected individuals into sub-
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clusters rather than with the GTEx ASD-unaffected individuals. The SPARK ASDunaffected individuals were siblings of SPARK ASD-affected individuals that were not
included in these analyses. However, if we can assume that the SPARK ASD-affected
siblings of the SPARK ASD-unaffected group follow similar genotypic trends as those in
the Discovery and Classification subsets, then it is fair to say that the ASD-unaffected
siblings are more likely to follow the ASD genotype pattern because of the inherent
familial relationships compared to unrelated controls. It is possible that the significant
variants identified in this study contribute to the hypothesis that the accumulation of
otherwise common variants can also confer ASD risk. Previous research has also shown
that ASD-unaffected siblings of ASD-affected siblings can still show milder symptoms of
ASD, even as high as 15% of siblings exhibiting a ‘broad autism phenotype’ (211–213).
Nonetheless, there seems to be no significant genetic differences between ASD-affected
individuals and unrelated ASD-unaffected siblings at the variants we have identified.
The significant variants in this study were associated with 174 tissue-specific
eQTLs derived from the GTEx database. Based on the log2aFC information of each
variant and the allele distributions between ASD-affected and ASD-unaffected
individuals, the direction of expression in ASD can be determined. Of the 174 eQTLs, 96
had higher gene expression in their associated tissue compared to 78 eQTLs with lower
gene expression (Additional File 2: Supplemental Table 4). When looking solely at the 27
eQTLs associated with a brain tissue, 8 had lower gene expression in ASD individuals
while 19 had higher gene expression (Table 2.1, Supplemental Table 2.4). CES1 and
MAN2C1 had the most GTEx brain associations. CES1, a drug metabolizer, has been
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shown to have significantly different mRNA levels in peripheral leukocytes of ASDaffected individuals and unrelated ASD-unaffected mothers of ASD-affected individuals,
compared to controls (214,215). Microdeletions in the area surrounding MAN2C1 have
been linked to gene expression of MAN2C1 in the brain, a lower verbal and non-verbal
IQ, and ASD (216–218).
When comparing the significant eQTLs to data published by PsychENCODE,
more brain related associations were found (Table 2.3). For example, POLR1B is
associated with a variant that falls into an acetylation peak that is active in the PFC, TC,
and CBC. POLR1B is a target of a microRNA (miR-365a-3p) that has shown to be
upregulated in ASD-affected individuals (219). The variant associated with SIRPB1 falls
within a PsychENCODE enhancer and has been identified as an eQTL in the brain.
SIRPB1 was deleted in a case study of monozygotic ASD twins, and has been linked with
impulsive-disinhibited personality, meaning the individuals struggle to control their
impulses, which has been implicated in ASD (220–222). One other example of an
association with PsychENCODE can be found in the CIDEA gene, which was identified
by our study and was shown to be significantly down-regulated in ASD-affected
individuals by PsychENCODE. CIDEA has shown to be down-regulated in obesity and
associated with ADHD, both of which often appear in tandem with ASD (223–227). In
total the eQTLs described here are evidence of tissue-specific regulation across both
brain and non-brain tissues. While it is likely that neurological traits originate in the
brain, ASD-affected individuals share common non-neurological traits as well. It is
possible that eQTLs are one avenue in which a variant can result in changes of gene
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expression across multiple tissues, like can be observed for genes CES1 and MAN2C1 in
this study. The significant variants and eQTLs discovered here will need to be further
investigated to elucidate if a global regulatory variant and its consequent tissue-specific
changes could be linked to ASD as a possible mechanism.
Limitations
One limitation of this study was the scope of the genome we were able to
investigate. Because the SPARK genotyping data was centered within and around genes,
there are possibly more significant variants in intragenic regions that we were not able to
investigate. An additional limitation is the population of ASD-affected individuals that
we chose to study. By removing individuals with environmental exposures and those that
had potentially inherited a large-scale genetic change from an ASD-affected parent, we
likely lost statistical power and the opportunity to discover additional variants. We hope
future studies will further investigate these regions and individuals.
Conclusion
ASD is a common neurological disorder characterized by a variety of phenotypic
traits and genetic associations. Here we investigated allelic distributions of variants
associated with tissue-specific eQTLs between an ASD-affected population and two
outside control populations to discover 30 significant variants. A neural network was then
used to classify two separate groups of ASD-affected and ASD-unaffected individuals
based on the genotypic profiles at the significant variants. For both populations, the
significant variants were able to correctly assign individuals to their respective group
with a higher accuracy (90-100%) compared to 30 random variants (30-70% accuracy).

46

These variants were associated with 34 genes and 49 tissues for a total of 174 tissuespecific eQTLs. Comparison of these features with PsychENCODE, a comprehensive
brain and ASD resource, showed that several of these variants exist within brain-specific
regulatory regions and several genes had been previously identified as differentially
expressed in ASD-affected individuals. Further research will be needed to validate if the
eQTLs discovered here and the consequent changes in tissue-specific gene expression
can result in the myriad of brain and non-brain phenotypic traits seen in ASD-affected
individuals.
Materials and Methods
GTEx eQTLs. Tissue-specific cis-eQTLs (version 8) were downloaded from the
GTEx website [https://gtexportal.org/home/datasets]. The most significantly associated
variant for each gene in each tissue was considered for analysis. The GTEx eQTLs with a
qval < 0.05 were retained, as recommended by GTEx. From these eQTLs, we were first
interested in the associated variants. The variant information included the locus
(chromosome and base position), as well as the reference and alternate alleles. Here, each
variant was listed as ‘chromosome_base-pair_reference-allele_alternate-allele’. Of the
eQTLs meeting the qval criteria, a list of variants was extracted.
Genetic Dataset Overview. This study used genetic data from the Simons
Foundation Autism Research Initiative SPARK Regeneron dataset released May 1, 2019,
which included whole-exome sequencing data, whole-genome genotyping data,
background information, and surveys for the ASD-affected individuals and their families.
For the two outside control groups, individual-level genotypes and background
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information were obtained from GTEx (phs000424.v8.p2) and population-level
genotypes were accessed from gnomAD (v3.1). To protect this data, the lab was granted
access to the GTEx and SPARK datasets through IRB approval and everyone on the
project underwent human subjects training. The data was stored on a private allocation on
Clemson’s Palmetto Cluster with access only available to those directly working on it.
All analyses were also completed on that allocation to protect the data from other users.
SPARK Dataset. Because of the genetic nature of the study, ASD-affected
individuals with possible environmental contributions to their diagnosis were excluded.
These conditions included: birth or pregnancy complications, premature birth, fetal
alcohol syndrome, and cognitive delays due to exposure or medical condition. Due to
genetic similarities in families, only one individual from each family was included in this
study. We limited this study to ASD-affected individuals with two ASD-unaffected
parents, as well studied solely Caucasian and African American individuals, excluding
those with mixed race. After taking these limitations into account there were 1,647
Caucasian ASD-affected individuals (1,300 males, 347 females) and 48 ASD-affected
African American individuals (40 males, 8 females) available for study.
GTEx and gnomAD Datasets. The GTEx VCF data included genotype calls for a
total of 838 people, including 715 Caucasian (472 males, 243 females) and 103 African
American individuals (71 males, 32 females). For the gnomAD dataset, the ‘Non-NeuroNFE’ subset was used, which included non-Finnish European individuals who were
either not enrolled in a neurological study or were designated as a control in a
neurological study (N = 37,543).
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Filtering VCFs. For SPARK and GTEx VCFs, genotype calls for each individual
were filtered for depth and genotype quality (DP>10, GQ>20) using bcftools. The
genotype calls that did not meet both thresholds were considered a no-call. VCFs were
then transformed into genotype matrices using JVARKIT tools published by Pierre
Lindenbaum (https://github.com/lindenb/jvarkit), where for each variant a ‘0’ denoted a
homozygous reference allele genotype, a ‘1’ denoted a heterozygous genotype, a ‘2’
denoted a homozygous alternate allele genotype, and a ‘-1’ denoted a no-call. From these
matrices the individuals within the Discovery and Classification subsets and their
genotypes at eQTL loci were extracted. Each variant within these subsets had to have
genotype calls for at least 90% of the individuals of interest in each Discovery and
Classification subset to be further considered.
Assembly of Discovery and Classification Subsets. The primary analysis of this
study used ASD-affected individuals from SPARK and ASD-unaffected individuals from
GTEx and gnomAD to identify variants with significantly different allele distributions at
eQTL associated loci. An overview of which can be seen in Figure 2.1. For the main
Discovery stage experiments using gnomAD and GTEx control groups, the SPARK
Caucasian Discovery subset was assembled by randomly picking 180 ASD-affected
males and females from the group of 1,647 described above. Similarly, 180 ASDunaffected males and females were randomly selected from the GTEx Caucasian
Discovery subset. As no individual-specific genetic information was available from
gnomAD, the summary information for the NFE-non-neuro population was utilized for
each variant. For the Classification stage experiments, two new subsets were introduced,
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the Caucasian and the African American Classification subsets. For the Caucasian
Classification subset, 60 SPARK ASD-affected males and females and 60 GTEx ASDunaffected males and females were randomly selected from those not included in the
Discovery subsets, making up a total subset of 240 individuals. For the African American
Classification subset, all 40 males and 8 females were selected from the African
American SPARK dataset, and 40 males and 8 females were randomly chosen from the
African American GTEx dataset, totaling 96 individuals. A severity subset was also
created from the SPARK Caucasian Discovery matrix (Supplemental Figure 2.1). The
severity subset included individuals from the SPARK Caucasian Discovery subset that
had provided corresponding phenotypic information. Of the 360 ASD-affected
individuals in the SPARK Caucasian Discovery matrix, 271 completed all three
phenotypic surveys (Developmental Coordination Disorder Questionnaire, Repetitive
Behavior Scale-Revised, and Social Communication Questionnaire). The scores across
all three surveys were added up and the 90 individuals with the highest and lowest scores
(denoted as most and least severe, 180 individuals total) were used in conjunction with 90
random GTEx individuals from the original SPARK Caucasian Discovery subset.
Discovery Stage: Finding Significant Variants, eQTLs, and Genes. In the
SPARK-GTEx and SPARK-gnomAD experiments within the Discovery stage, a loci
summary report was constructed for each experiment that included the number of
reference and alternate alleles for each variant across the ASD-affected and ASDunaffected individuals. A Fisher’s Exact Test (from SciPy’s stats module) was then
performed on the corresponding allelic data for each variant, therefore assigning each one
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a p-value. The variants were sorted from lowest to highest based on their p-value and
consequently ranked. To prevent false-positives, a Benjamini-Hochberg correction was
applied at a false discovery rate of 1%. To do so, a critical value was calculated for each
variant. Moving down the ranked list, the last variant in which the p-value was less than
the critical value was noted, and its corresponding p-value was deemed to be the cutoff.
All variants with a p-value less than the cutoff were then deemed “significant”. This
yielded a list of variants for each experiment in which ASD-affected and ASD-unaffected
individuals have significantly different allelic distributions (Supplemental Table 2.1 and
Supplemental Table 2.2). The variants found across both experiments were merged,
creating a group of consensus “significant variants” (Supplemental Table 2.3). This list of
significant variants was cross-referenced with the GTEx eQTLs (with a qval < 0.05) to
make a list of “significant eQTLs” (Supplemental Table 2.4). The information for tissuespecific information for associated eQTLs is also available (Supplemental Table 2.4).
The genes associated with the significant eQTLs were extracted to form a list of
“significant genes.” A summary of the eQTLs and variants analyzed can be found in
Table 2.1. The genes and their tissue associations are included in Table 2.2.
Expression of Significant Genes in Brain Tissues. To investigate how the
significant genes were expressed in the brain, a matrix of TPM expression values for
2564 GTEx brain samples from thirteen brain tissues were downloaded from the GTEx
portal and processed [https://gtexportal.org/home/datasets]. The RNAseq expression
values were log2 transformed, quantile normalized, and 78 outliers removed
(Kolmogorov-Smirnov test (KS Dval>0.15) using GEMprep
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[https://github.com/SystemsGenetics/GEMprep.git]. This matrix was used to make a
heatmap, which was generated using the R (v4.3) package ComplexHeatmap (Figure
2.2). Genes (rows) were grouped using hierarchical clustering. Columns were ordered
based on the 13 brain tissues as indicated on the heatmap.
Variant Associations with Active Brain Regulatory Regions. We were interested
in finding more relevant associations for the significant eQTLs, especially related to the
brain. This was done by downloading files of interest from PsychENCODE
[http://resource.psychencode.org]. The enhancers are active specifically in the prefrontal
cortex (PFC), while the three acetylation peak files represent the prefrontal cortex (PFC),
the temporal cortex (TC), and the cerebellar cortex (CBC). The PFC enhancer file was
available in hg38, but the acetylation peak files were published in hg19. Therefore, the
coordinates in the acetylation peak files were transferred to hg38 using UCSC’s liftOver
[https://genome.ucsc.edu/cgi-bin/hgLiftOver]. After all files were in the same genome
build, the variants and genes of the significant eQTLs were compared to the brainspecific associations. The associations were noted in Table 2.3 and Supplementary Table
2.4.
Classification Stage: tSNE. The SPARK-GTEx Caucasian Discovery subset,
SPARK-GTEx Caucasian Classification subset, and SPARK-GTEx African American
Classification subset all underwent visualization using tSNE. For the SPARK-GTEx
Caucasian Discovery subset of individuals, the genotype profiles of the significant
variants and all variants tested were used as inputs (Figure 2.3). For the Classification
subsets, instead of using all tested variants as a comparison, 30 variants were randomly
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chosen (Figure 2.4). For each tSNE plot, the input matrix first underwent principal
component analysis (PCA), which was then followed by tSNE. The sklearn Python
package was used for both computational processes.
Classification Stage: Neural Network. Initially, the data and label file were loaded
and split into an 80-20 train-test split. The data was a two-dimensional matrix of
genotypes that corresponded to each sample at the variants of interest. The genotypes
were a discrete value ranging from -1 to 2. The label file mapped the sample to its label,
either “affected” or “unaffected”. The input values were then converted to one-hot
encoding. Next, a multilayer perceptron model was constructed with PyTorch for binary
classification. The model consisted of 3 hidden layers and an output layer with 120, 84,
10, and 1 neuron respectively. A dropout layer was in between each hidden layer and
every hidden layer applied the ReLU activation function. The model was trained on 80%
of the input data using a batch size of 8 for 1000 epochs. The BCEWithLogitsLoss
function was used during training to combine a sigmoid layer and the loss function for
binary classification. Every epoch, after the model updates its weights, a forward pass
was done on the test set to calculate the accuracy. The sigmoid activation function was
used to estimate the probability that the sample belongs to the affected or unaffected
class. Once finished, the accuracy of the test set was plotted every 50 epochs (Figure
2.5).
Secondary Analysis: Finding Significant Variants within SPARK Dataset. To
conclude the study a final analysis was performed comparing the allelic distributions of
SPARK-ASD affected individuals and SPARK-ASD unaffected individuals at eQTL
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variants (Figure 2.6). The same population of 360 Caucasian SPARK ASD-affected
individuals used in the primary Discovery analysis was used again here. The group of
SPARK ASD-unaffected individuals were siblings of individuals diagnosed with ASD
that were not included in the Discovery subset. Therefore, they were not diagnosed with
ASD, but they have an ASD-affected sibling who was not in the Discovery subset, so no
familial substructure would exist between the two groups. A total of 1,651 ASDunaffected siblings (855 males and 796 females) met these criteria. Of those 1,651
individuals, 180 males and 180 females were randomly chosen. The same analysis used
in the primary Discovery analysis was completed again here. A Fisher’s Exact Test was
completed at each eQTL variant, comparing the distribution of alleles between the ASDaffected and ASD-unaffected groups, a p-value was assigned, and a Benjamini-Hochberg
procedure was used to correct for multiple hypothesis testing. After correction, no
variants were identified in which there was a significant difference in the allele
distributions across the two groups (Additional File 2: Supplemental Table 6). To
visualize this, a tSNE plot was used with the input of genotype profiles at previously
discovered significant variants for the SPARK Caucasian ASD-affected individuals,
SPARK Caucasian ASD-unaffected individuals, and GTEx Caucasian ASD-unaffected
individuals (Figure 2.6). The PCA and tSNE commands were both from the sklearn
Python package.
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CHAPTER THREE
IDENTIFICATION OF CONDITION-SPECIFIC BIOMARKER SYSTEMS IN
UTERINE CANCER
Note: This chapter is currently under review as a manuscript entitled "Identification of
Condition-Specific Biomarker Systems in Uterine Cancer” by Allison R. Hickman,
Yuqing Hang, Rini Pauly, and Frank A. Feltus for publication in G3.

Abstract
Uterine cancer is the fourth most common cancer among women, projected to
affect 66,000 US women in 2021. Uterine cancer often arises in the inner lining of the
uterus, known as the endometrium, but can present as several different types of cancer,
including endometrioid cancer, serous adenocarcinoma, and uterine carcinosarcoma.
Previous studies have analyzed the genetic changes between normal and cancerous
uterine tissue to identify specific genes of interest and further investigate their associated
gene interactions. Here we used Gaussian Mixture Models to build condition-specific
gene co-expression networks for endometrial cancer, uterine carcinosarcoma, and normal
uterine tissue. We then incorporated uterine regulatory edges and investigated potential
co-regulation relationships. These networks were further validated using differential
expression analysis, functional enrichment, and a statistical analysis comparing the
expression of transcription factors and their target genes across cancerous and normal
uterine samples. These networks allow for a more comprehensive look into the biological
networks and pathways affected in uterine cancer compared to previous singular gene
analyses. We hope this study can be incorporated into existing knowledge surrounding
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the genetics of uterine cancer and soon become clinical biomarkers as a tool for better
prognosis and treatment.
Introduction
Uterine cancer is the most common gynecological cancer and the fourth most
common cancer overall among women (91,228). The incidence of uterine cancer is
increasing each year with an estimated 66,000 new cases projected for 2021 in the US
(228,229). The five year survival rate for all uterine cancers is roughly 81%, but differs
significantly based on cancer subtype and stage (229,230).
Uterine cancer can arise in the endometrium, the lining of the uterus, or in the
myometrium, the middle uterine layer composed of muscle. Endometrial cancer is more
common than uterine sarcoma (cancer of the myometrium), making up roughly 85% of
all uterine cancer cases (231). Endometrial cancer is an overarching category of cancers.
Specific subtypes include, but are not limited to, endometrioid cancer, serous
adenocarcinoma, clear cell carcinoma, and uterine carcinosarcoma. Endometrioid cancer
is the most common of the endometrial cancers and has the best prognosis as a type 1
estrogen-dependent uterine cancer (94). In those cases the unopposed estrogen could stem
from estrogen-only forms of birth control, the breast cancer drug tamoxifen, or obesity,
among other causes (94,232,233). Serous adenocarcinoma, clear cell carcinoma, and
uterine carcinosarcoma are rarer, each accounting for 3-10% of endometrial cancer cases
(228,230). Serous adenocarcinoma and clear cell carcinoma usually arise from atrophied
endometrium (234). These are considered estrogen-independent (type 2) and are more
aggressive than type 1 uterine cancer (94). They are usually diagnosed after the cancer
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has spread beyond the uterus, therefore leading to a poorer prognosis (234). Uterine
carcinosarcoma (UCS) is a more distinct subtype as it seems to be a cancer of both the
endometrium and the myometrium (230). Based on recent research of the cellular
morphology, it is more likely that the initial mutation begins in the endometrium and
spreads to the myometrium (7,230). Because of this, uterine carcinosarcoma is considered
a subtype of endometrial cancer. Similar to serous adenocarcinoma and clear cell
carcinoma, uterine carcinosarcoma has a poor prognosis (~35% survival rate after five
years) and accounts for 15% of deaths associated with uterine cancer (230,235).
To better diagnose, prognose, and treat uterine cancer, biomarkers can be used. A
biomarker is a characteristic that indicates a normal or pathogenic process (236).
Biomarkers can come in many forms, such as oxidative damage in an individual’s plasma
to measure the progression of Parkinson’s disease (237), inflammation markers in blood
to predict someone’s risk for cardiovascular disease (238), and characteristics of EEGs to
diagnose major depressive disorder (237–239). Many cancer-specific genetic biomarkers
have also been identified. Some examples include mutations in EGFR and BRAF for
non-small cell lung cancer, DNA methylation patterns to determine stomach cancer
metastasis, and RNA expression of SChLAP1 to predict metastasis of prostate cancer
(240–242). Many genetic mutations have already been identified as biomarkers of uterine
cancer, many of which we discover or re-discover here.
The Cancer Genome Atlas (TCGA) has investigated both UCS and UCEC
cancers. They have identified genes that tend to be mutated across both cancer types,
such as TP53, PTEN, PIK3CA, and PPP2R1A (7,100). While some are specific to solely
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UCEC (FGFR2, CTNNB1, POLE), others have only been associated with UCS (RB1,
ZBTB7B, U2AF1) (7,100). Translocations have been found with genes involved in the
WNT and PI(3)K pathways, among others (7). Microsatellite instability is more common
in endometrioid cancer compared to serous adenocarcinoma and UCS (7). UCS and type
II UCEC cases tend to have more CNV events compared to UCEC type I cases (7,243).
Endometrial cancer can also appear in conjunction with Lynch syndrome, which is
usually due to mutations in genes involved with DNA mismatch repair (244). These
genes include MLH1, MSH2, MSH6, and PMS2, with mutations in MSH6 carrying the
most risk for developing endometrial cancer (244,245).
In this study we assemble groups of related biomarkers, known as a biomarker
system or biosignature, that are specific to normal uterine tissue and cancerous uterine
tissue. We are assembling two types of biomarker systems: gene co-expression networks
(GCNs) and gene regulatory networks (GRNs). Co-expressed genes are discovered by
analyzing gene expression data and finding gene pairs that have significantly similar
expression patterns. These co-expressed gene pairs are then assembled to form a GCN. A
GCN-GRN is constructed by merging the GCN with directed tissue-specific regulatory
edges (transcription factor to target gene). These networks have been used to identify
biomarkers for many complex diseases including Alzheimer’s disease, hepatocellular
carcinoma, breast cancer, and kidney cancer (246–249). Networks like these, or even
sub-networks, are reproducibly better at classifying disease compared to singular genes
(105,250). Especially in complex disease, such as cancer, there are multi-gene pathways
responsible for the diagnosis, rather than a small group of genes of interest (251,252).

58

The associations of those molecular interactions within each condition-specific network
allows for a more comprehensive view of the cellular environment compared to singular
gene associations.
Several other studies have built gene co-expression networks specific to
endometrial cancer to find genes of interest. One identified several hub genes related to
stage, grade, and type of endometrial cancer (253). Another study was interested
specifically in the co-expression patterns of gene AKT. They were able to identify six coexpressed genes (PBK, BIRC5, AURKA, GTSE1, KNSTRN, and PSMB10), some of
which were also able to predict prognosis (254). Other studies have discovered
additional hub genes with prognostic power, TICRR, PPIF, and ANO1 (255,256). These
previous endometrial cancer studies have all used weighted gene co-expression network
analysis (WGCNA) to build the GCNs, while we have taken a different approach using
Gaussian Mixture Models (GMMs) prior to pairwise gene correlation tests. Our approach
allows for analysis of genes that are involved in more than one biological process (257).
For example, a gene can be involved in one process at a high expression level and
another at a low expression level. In this analysis, the GMMs can differentiate between
the two expression levels and test each for co-expression edges, whereas WGCNA
cannot.
Uterine cancer is one of the most common cancers among women, and the
incidence is increasing each year. In this study we aimed to explore the genetic
differences between normal and cancerous uterine tissue. By building uterine conditionspecific biomarker systems through the use of GMMs, we can contribute to the growing
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literature of biological associations and changes in genic relationships to better
understand, and potentially better diagnose and treat, uterine cancer.
Results
Segregation of Cancer and Control Individuals Based on Gene Expression Profiles
A uterine gene expression matrix (GEM) was constructed from normalized and
batch-effect-corrected FPKM files for TCGA and GTEx uterine samples, published by
Wang et al [https://doi.org/10.6084/m9.figshare.5330593] (258). The GEM includes gene
expression information for 19,304 genes across 82 GTEx Normal samples, 23 TCGA
Normal samples, 141 TCGA-UCEC samples, and 47 TCGA-UCS samples. To visualize
the GEM, we used t-distributed stochastic neighbor embedding (t-SNE), a technique used
to visualize high dimensional data in a two-dimensional scatterplot (259). The tSNE
visualization of the GEM can be found in Figure 3.1, which shows the spatial
representation of the 293 samples, based on their gene expression profiles. The cancer
samples, TCGA-UCEC and TCGA-UCS (represented by green and pink dots,
respectively), can be seen segregating separate from the normal samples, GTEx-Normal
and TCGA-Normal (red and blue, respectively). One TCGA-UCEC outlier was boxed
and brought in closer to allow for better visibility of the two main clusters.
Constructing Condition-Specific Gene Co-expression Networks
To construct condition-specific gene co-expression networks (csGCNs) from the
uterine GEM, we first used KINC (Knowledge Independent Network Construction)
[https://github.com/SystemsGenetics/KINC]. KINC identifies gene co-expression edges
that are specific to one condition. The conditions of interest for this study are normal
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Figure 3.1: t-SNE Plot of Uterus Gene Expression Matrix.
A tSNE plot of all samples included in the Uterus GEM. The color of each dot represents the group that
sample belongs to. The boxed outlier UCEC sample was moved closer to the other samples to avoid
whitespace.

uterine tissue (GTEx-Normal), and two types of cancer (TCGA-UCEC and TCGA-UCS).
KINC uses GMMs to cluster samples, then performs a pairwise gene correlation analysis
on each cluster. Only clusters with greater than 25 samples were considered, so the
TCGA-Normal samples were not used for any further analyses. Condition specific gene
pairs with a correlation less than -0.5 or greater than 0.5 were considered for further
testing. Low-powered edges within each cluster were removed, and p-values were
assigned to those remaining. Condition specific networks were created and edges within
each network with a p-value > 0.001 were removed. Biased edges were also removed,
and remaining edges were ranked based on their p-values and similarity scores. Through
this process, KINC built three csGCNs: GTEx-Normal (14,044 edges, 4,372 genes),
TCGA-UCEC (2,861 edges, 1,496 genes), and TCGA-UCS (24 edges, 39 genes). The
GTEx-Normal had the highest average connectivity (k=6.42), followed by UCEC
(k=3.82), and finally UCS (k=1.23). Further details on GCN construction are provided in
the Materials and Methods.
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Before further investigating these csGCNs, we wanted to analyze the gene
expression patterns of the genes within the networks. More specifically, we were
interested in determining if the genes within the csGCNs were differentially expressed
between each respective cancer condition and GTEx-Normal. A total of 20,242 and
19,316 genes were analyzed for UCEC and UCS, respectively. The differential gene
expression analysis was performed using DESeq2_1.30.1 in R 4.0
(https://bioconductor.org/packages/release/bioc/html/DESeq2.html). Genes had to have
expression values for at least fifty samples for each analysis. After the analysis was
completed, genes with an adjusted p-value > 0.05 were dropped. In total 14,551 and
13,898 genes were found to be significantly differentially expressed in the comparison of
GTEx-Normal with UCEC and UCS, respectively (adjusted p-value < 0.001).
The genes within each GCN were merged with the differential expression analysis
to denote the differential expression status of each csGCN gene. Of the 1,496 genes in the
UCEC-specific network, 1,333 were differentially expressed, accounting for roughly 89%
of the genes. In the UCS-specific network 35 of the 39 genes were differentially
expressed, accounting for 90% of the genes. For the UCEC csGCNs, when observing
only the DEGs and DEG edges (edges in which both nodes are DEGs), there is a slight
increase in k. When similarly assessing GTEx-Normal and UCS, k slightly decreases. The
csGCNs are represented in Figure 3.2 (UCEC), Figure 3.3 (UCS), and Supplemental
Figure 3.1 (GTEx-Normal). In those Cytoscape visualizations, the genes are represented
as blue nodes, and co-expression edges are depicted as grey lines. Furthermore, the text
color of each node denotes if the gene is up-regulated in cancer (green), down-regulated
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in cancer (red), or was not significantly different between cancer and GTEx-Normal
(black). The attributes of each GCN network can be found in Table 3.1. The complete list
of condition-specific edges and each node’s DEG status can be found in Supplemental
Table 3.1.

Table 3.1. Uterus Condition Specific Gene Co-Expression Network Global
Attributes
Sample Condition Samples Genes
Edges
k
DEG Genes
DEG Edges
GTEx_Normal
82
4372
14044
6.42
3312
10610
TCGA_UCEC
141
1496
2861
3.82
1333
2638
TCGA_UCS
47
39
24
1.23
35
19

Figure 3.2: Cytoscape Visualization of UCEC Gene Regulatory Network.
UCEC-specific gene regulatory network containing co-expression and regulatory edges.
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DEG k
6.41
3.96
1.09

Figure 3.3: Cytoscape Visualization of UCS Network.
UCS-specific network containing co-expression and regulatory edges.

Integration of Regulatory Edges to Construct Condition-Specific Gene Regulatory
Networks
Directed regulatory edges derived from the GTEx database and published by the
Glass Lab at Harvard were downloaded
[https://sites.google.com/a/channing.harvard.edu/kimberlyglass/tools/gtex-networks]. We
extracted the uterine regulatory edges and merged them with the co-expression edges in
our csGCNs to create condition-specific gene regulatory networks (csGRNs). Similar to
the GCN construction, the transcription factors (TFs) were also subject to the differential
expression analysis. Figure 3.2 and Figure 3.3 both contain these regulatory edges
(denoted as arrowed edges) for UCEC and UCS, respectively. Their regulation pattern in
cancer is denoted like that of the genes described above (red: significantly down-
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regulated in cancer, green: significantly up-regulated in cancer, black: no significant
difference in expression).
Another step we included in GRN assembly was a ratio analysis comparing the
expression ratio of the TF to the target gene (TR). For each regulatory edge, the TF/TR
ratio was compared between GTEx-Normal samples and the respective cancer samples
using a student’s t-test. In Figure 3.2 and Figure 3.3 the regulatory edges with
significantly different ratios (p-value < 1E-5) are shown as orange arrowed edges, and
those without a significantly different ratio between normal and cancer conditions are
shown as black arrowed edges. More detailed descriptions of these analyses can be found
in Materials and Methods.
Of the 1,101 regulatory edges investigated for the UCEC GRN, 356 had a
significantly different TF/TR ratio between GTEx-Normal and UCEC samples and
consisted of a TF and TR that were both differentially expressed. Because those edges
meet three separate requirements (differentially expressed TF, differentially expressed
TR, and significant TF/TR ratio), they will be referred to as ‘significant’ regulatory
edges. Of the 356 significant edges, 163 had a lower TF expression and higher target
gene expression in UCEC. The least common pattern found in the network was one in
which both the TF and TR were both upregulated in UCEC. In the UCS-specific GRN
there were only three regulatory edges that met the significance criteria, none of which
had the same expression pattern. A summary of the distribution of edges across the four
possible expression patterns (TF and TR up, TF and TR down, TF up and TR down, TF
down and TR up) can be found in Figure 3.4. A heatmap visualization with DEG status
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of TFs and TRs, TF and TR expression pattern in cancer, and designation of significant
TF/TR ratios can be seen in Supplemental Figure 3.2.

Figure 3.4: Expression Patterns of Transcription Factors and Target Genes in Cancer-Specific
Regulatory Edges.
Distribution of expression patterns and ratio analyses results for regulatory edges in UCEC and UCS
networks compared to GTEx.

Within these csGRNs, we were particularly interested in potential co-regulation
relationships, so we selected “triangle” sub-networks for further study. Here, we define a
triangle relationship as one in which a TF regulates two TRs that are connected by an
edge. These triangle relationships were extracted from the UCEC GRN to create what we
have deemed the “UCEC triangle GRN.” As seen in Figure 3.5 the UCEC triangle GRN
is made up of four TFs and seven genes, almost all of which have a significantly lower
expression in UCEC compared to normal, as noted by the red gene names. Likely
because of its smaller size, no triangle relationships were present in the UCS GRN, so
therefore there is no corresponding triangle GRN. The attributes of the UCEC triangle
GRN can be found in Table 3.2 and the DNA mutation rates for these genes in UCEC
can be found in Supplementary Table 3.7.

66

Figure 3.5: Cytoscape Visualization of UCEC Triangle Network.
A UCEC-specific triangle network in which transcription factors are associated with both nodes of a coexpression edge.

Table 3.2. Uterus Condition Specific Gene Regulatory Network Global Attributes
Sample Conditon
Samples
GTEx_Normal
82
TCGA_UCEC
141
TCGA_UCS
47
TCGA_UCEC_Triangle
141

Edges
17516
3976
41
31

Genes
4281
1462
39
7

TFs
454
361
15
4

TF/Gene
91
34
0
0

k
7.26
4.28
1.52
5.64

Significant DE
Edges
Genes
11193
3235
2994
1304
22
32
18
5

DE
DE
DEG
TFs TFs/Genes k
285
77
6.32
102
21
4.20
3
0
1.26
4
0
4.00

Functional Enrichment of Differentially Expressed Genes within Condition-Specific
Gene Co-expression Networks
Functional enrichment was performed for the genes within the UCEC GCN, the
UCS GCN, and the UCEC triangle GRN using ToppFun
[https://toppgene.cchmc.org/enrichment.jsp]. ToppFun uses a set of genes as input to
identify associations of those genes with published annotations, such as microRNAs,
phenotypes, and cell types. The DEG list for each csGCN was used as the input, and the
default full gene set as the background. The UCEC DEG list (n = 1,333 genes) had
16,305 significant associations (qval FDR B&H < 1E-5). Several associations of interest
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included ovarian cancer (qval FDR B&H = 8.51E-73), endometrial cancer (qval FDR
B&H = 2.39E-54), cervical cancer (qval FDR B&H = 3.03E-45), and normal endometrial
tissue (qval FDR B&H = 6.56E-43). Functional enrichment of the UCS DEG list (n = 35)
yielded four significant associations (qval FDR B&H < 1E-5), of which included basal
lung cells (qval FDR B&H = 3.46E-6), immune cells (qval FDR B&H = 3.46E-6), and
‘genes upregulated in uterus upon knockout of BMP2’ (qval FDR B&H = 6.62E-6).
Functional enrichment of the genes within the UCEC triangle GRN was also performed,
which yielded 110 significant associations (qval FDR B&H < 1E-5). These associations
included many TCGA cancers, like that of the bladder, stomach, lung, and ovary, as well
as mesenchymal cells. The functional enrichment associations for the DEGs within the
UCEC, UCS, UCEC triangle, and GTEx networks can be found in Supplemental Table
3.6.
Discussion
In this study, we constructed uterine condition-specific gene relationship networks
where genes are defined by co-expression and regulatory edges. Our csGCN search
space was a unified uterine gene expression matrix containing cancerous (TCGA-UCEC
and TCGA-UCS) and normal (TCGA-Normal and GTEx-Normal) tissue samples. The
directed GRN graph was derived from annotated uterine gene regulatory relationships.
Thus, our final gene relationship graph for uterine derived normal and tumor samples is
built from the appropriate tissue.
As shown in Figure 3.1, the global RNA expression profiles for normal and
diseased uterine samples segregate due to the overall gene expression patterns, with the
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exception of one TCGA-UCEC outlier that can be seen in the top left corner of the tSNE
visualization. To identify genetic expression subsystems that discriminate between
conditions (i.e., biomarker systems), we assembled csGCNs for two uterine cancers
(UCEC and UCS) and normal uterine tissue (GTEx-Normal). The co-expression edges
were discovered using KINC, a program that finds gene pairs based on similarities in
their expression patterns within each respective condition. TCGA-Normal samples could
not be processed through KINC due to the limited number of samples, so therefore, they
were excluded from the remaining analyses. To further validate these csGCNs, a
differential expression analysis (DESeq2) was used to find co-expression edges that have
a significantly different expression pattern between cancer and normal samples. The
DESeq2 results can be found in Supplemental Tables 3.2 and 3.3, a summary of which
can be found in Table 3.1.
We then incorporated directed regulatory edges (transcription factor to target
gene) into each respective GCN to build condition-specific gene regulatory networks
(csGRNs). This was done by adding the regulatory edges into each GCN if the target
gene was present in the network. In the UCEC GRN, there were several instances where
one transcription factor was associated with both nodes of a co-expression edge, a
relationship we dubbed a “triangle”. These potential co-regulation triangle relationships
were extracted, which constitutes another GRN, the UCEC triangle GRN. Finally, we
wanted to further investigate these regulatory edges by comparing the TF/TR ratio for the
cancer and normal samples, then use a t-test to determine if the ratios between the two
groups were significantly different. This was completed for the regulatory edges in the
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UCEC, UCS, GTEx, and UCEC triangle GRNs. For the GTEx GRN, the genes and TFs
had to be differentially expressed in both UCS and UCEC, and regulatory edges had to
have a significantly different TF/TR ratio compared to UCEC and UCS. The regulatory
edges with significantly different TF/TR ratios can be seen as orange arrowed edges in
Figure 3.2 (UCEC GRN), Figure 3.3 (UCS GRN), Figure 3.5 (UCEC triangle GRN),
Supplemental Figure 3.1 (GTEx GRN) and are documented in Supplemental Table 3.4
(Cancer GRN edges) and Supplemental Table 3.5 (GTEx GRN edges).
UCEC Biomarker Systems.
The UCEC triangle GRN was constructed due to our interest in possible coregulation of csGCN edges. This triangle sub-network drastically reduced the size of the
overall UCEC GRN, allowing us to further investigate these genes of interest. Five of the
seven genes in the UCEC Triangle GRN are not included in the GTEx-Normal GCN.
TMEM119 and CDH11 are the exceptions, each with two co-expression edges in the
normal uterine network. Meanwhile all seven genes are highly connected in the UCECspecific GCN, associated with a total of 106 other genes (mean=28 edges/gene, median =
20 edges/gene). GPR124 and CDH11 have the highest and lowest connectivity with 66
and 6 co-expression edges, respectively. It is possible that these changes in co-expression
patterns between the UCEC and GTEx-Normal GCNs are due to mutations in the cis or
trans DNA sites.
KINC, DESeq2, and the TF/TR ratio analysis have all been completed based on
RNA expression values found in the uterine GEM. The Genomic Data Commons Data
Portal (GDC) contains information on DNA mutation rate and CNV occurrence rate for
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the UCEC samples from our analysis, as well as 389 additional samples that have been
added since the uterine GEM was created by the Wang Lab. This platform allows for
comparison of mutation rates for our genes of interest with other cancer projects,
including other TCGA projects. The number of projects that investigated these genes
ranges from 21 to 35. Of the eleven nodes (7 genes, 4 TFs) in the UCEC Triangle GRN,
nine had the highest mutation rates in TCGA-UCEC. For LDB2 and TMEM119 the
highest mutation rate was in TCGA-SKCM, a melanoma study, and was followed
immediately by TCGA-UCEC. A summary of the DNA mutations rates of these genes
can be found in Supplemental Table 3.7.
When investigating the CNV occurrence rate for the UCEC Triangle GRN genes
and TFs, UCEC consistently had a lower rate of CNV events at those genes compared to
UCS. For example, when investigating TSHZ3 TCGA-UCEC ranked 7th highest in CNV
occurrence rate with 60 events out of 510 cases (11.76%), while TCGA-UCS ranked #1
with 21 events out of 56 cases (37.5%). While initially we expected UCEC CNV events
to be more common, given they are specific to a UCEC network, this seems to reflect the
results in TCGA’s comprehensive UCEC study where UCS samples were significantly
more likely to be characterized by CNV events compared to endometrioid samples (7).
These CNV rates can also be found in Supplemental Table 3.7.
There are several previously reported genes with DNA mutations specific to
UCEC including FGFR2, CTNNB1, and POLE (7). FGFR2 and CTNNB1 were not
included in the final DEG results and had no condition-specific edges. POLE was not
considered a DEG in the UCEC vs GTEx-Normal analysis (padj = 0.033), but did have
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co-expression edges with PHF1, ABRACL, SPAG5, STC2, and CMYA5 in the GTExNormal GCN. POLE was not present in the UCEC-specific GCN.
UCS Biomarker Systems.
The TCGA landmark paper also identified several genes specific to UCS with
common mutations (100).These include RB1, ZBTB7B, and U2AF1, each of which was
found to be mutated in 4-11% of samples. In our analysis RB1 and U2AF1 were not
found to be differentially expressed in UCS samples (p-adj = 4.32E-5 and 6.36E-3,
respectively). Like the other genes listed above, it is possible that the DNA mutations did
not make a significant difference in the mRNA expression. ZBTB7B was not included in
the final differential expression results, due to pre- or post- analysis filtering.
Combined UCEC and UCS Biomarker Systems.
Previous studies have found several commonly mutated genes for both UCEC and
UCS tumors: TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and KRAS (100). Of these six
genes, five of them (TP53, PTEN, PPP2R1A, FBXW7, and KRAS) were all found to be
differentially expressed in our study. PIK3CA was not included in the final differential
expression results. However, when looking between condition-specific networks we only
observe a change in gene co-expression patterns for the KRAS gene when comparing
UCEC and GTEx samples. In UCEC samples KRAS is co-expressed with CDON and
FZD4, while it is co-expressed with TSPAN2 in the GTEx-Normal samples. One possible
mechanism that could be attributed to this change is through the association of TFs.
However, there were no known TFs that regulate KRAS in the uterus. Instead, the change
in the co-expression relationships could be due to the mutation rate, as KRAS is mutated
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in roughly 25% of UCEC cases (260). Other possibilities include epigenetic
modifications, associated microRNAs, or other cellular interactions, which could be
investigated in a future study. Regarding the remaining genes listed above, there were no
condition-specific edges. While they were differentially expressed between UCS and
GTEx-Normal, KINC did not find any changes in gene co-expression relationships
between UCS and normal uterine tissue. It is possible that although those genes are
relatively more frequently mutated in uterine cancer, there are no changes in the gene
expression patterns.
Other genes have also been previously identified that had mutations in both
UCEC and UCS (100). These include CDH4, ARID1A, ARHGAP35, SPOP, and
PIK3R1. CDH4 was not found to be differentially expressed in UCEC or UCS samples.
ARHGAP35 was not found to be differentially expressed in UCS samples and was
dropped in pre- or post- processing for the UCEC differential expression analysis.
ARID1A was also absent from the differential analysis results for both UCEC and UCS
analyses. SPOP was found to be differentially expressed in both UCS and UCEC samples
and had several condition-specific relationships. In UCEC SPOP is co-expressed with
TOM1L1 and C2ORF15, and co-expressed with many genes in GTEx-Normal
(PPP1R12B, H2AFY, BZW2, TPM3, LRRC59, COPG1, HLF, and EIF4G1). SPOP has
no associations of annotated TFs in the uterus, so it is possible that the changes in coexpression edges could be due to the mutations. PIK3R1 has been shown to have
mutations in both UCEC and UCS, but more commonly in UCEC (100). In our study,
PIK3R1 was not differentially expressed in UCEC (padj = 2.41E-4), but was found to be
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differentially expressed in UCS (padj = 3.08E-12). It did not have any condition specific
co-expression edges.
Uterine cancer is one of the leading cancers among women in the US. Because of
this, we were interested in using bioinformatic tools to investigate the genes and their
relationships that differentiate endometrial cancer and uterine carcinosarcoma from
normal uterine tissue. We accomplished this by constructing and investigated gene coexpression and regulatory networks for normal and cancerous conditions in the uterus,
and validating them using differential expression, functional enrichment, and a ratio
analysis of expression data for regulatory relationships. These networks add to the
growing knowledge of uterine cancer biomarker systems and help elucidate the altered
biological pathways that occur. In addition, we aim to better characterize uterine cancer
by pursuing further investigations into the two distinct types of endometrial cancer,
specifically endometrioid carcinoma and serous adenocarcinoma. In total we hope this
knowledge can be used to better prognose and develop treatments for individuals
impacted by these uterine cancers in the future.
Materials and Methods
GEM Construction. The FPKM files for all uterine samples (TCGA-Normal,
TCGA-UCEC, TCGA-UCS, and GTEx-Normal) and their corresponding sample
annotation matrices were downloaded from the dataset published by Wang et al
[https://doi.org/10.6084/m9.figshare.5330593] (258). The FPKM files were quantile
normalized and corrected for batch effects before downloading. Using GEMprep, they
were combined into one large, combined GEM using the merge function. This was
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followed by the normalization function to perform a log2 transformation, quantile
normalization, and a Kolmogorov-Smirnov test to remove outliers (KS Dval > 0.15)
[https://github.com/SystemsGenetics/GEMprep.git]. The KS test did not find any outliers.
The final GEM includes gene expression information across 19,304 genes in 82 GTEx
Normal samples, 23 TCGA Normal samples, 141 TCGA UCEC samples, and 47 TCGA
UCS samples. This GEM was visualized via a tSNE plot using the visualize function in
GEMprep (Figure 3.1).
GCN Construction. To construct a gene co-expression network from the uterine
GEM, the Knowledge Independent Network Construction (KINC) software was used on
a NVIDIA DGX-2 system. [https://github.com/SystemsGenetics/KINC]. KINC v3.4.2
was pulled from GitHub into a Docker environment. KINC uses Gaussian Mixture
Models (GMMs) to identify clusters, then undergoes a correlation calculation for each
gene pair. This is done using KINC’s similarity function. Condition-specific clusters with
at least 25 samples were subject to Spearman correlation. Because of the minimum
sample requirement, the TCGA-Normal samples were dropped from the analysis at this
time. In the GMM analysis, all FPKM values less than 0 and more than 15 were ignored.
After the GMM analysis, the correlation step was performed on each cluster. When
performing the pairwise gene correlation analysis, the minimum and maximum number
of clusters for each pair were 1 and 5, respectively. The condition-specific gene pairs
with correlation values greater than or equal to 0.5 and less than 1 were considered for
further analysis. Using KINC’s corrpower function, a power analysis test was used on
each individual cluster to remove those that were underpowered. Type I error was limited
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to 0.001 significance using the alpha setting and type II error was limited to 20% using
the power setting. Next, KINC’s cond-test function completed condition-specific filtering
using a hypergeometric test to assign p-values to each edge. KINC’s extract function then
restricted network edges to those with a p-value of less than 0.001 and consequently
created condition-specific subnetworks. It was possible that biased edges were present in
the networks due to a lack of differential cluster expression or unbalanced missing data.
To remove those potential biased edges, the kinc-filter-bias.R script from KINC’s
companion R library (KINC.R) was used. This decreased the total number of edges
across all networks from 28,231 to 16,929. Summary plots were generated using
KINC.R’s kinc-make-summary-plots.R script. Edges within each condition-specific
network were then ranked using KINC.R’s kinc-filter-rank.R script.
The condition specific GCNs were then overlapped with the results from the
differential expression analysis. The DEG status of each node and its corresponding
expression pattern in cancer is denoted by the color of the gene name in the cytoscape
figures. For the GTEx specific GCN, a gene had to be differentially expressed in the
same direction in both UCEC and UCS DESeq analyses to be in labeled as such. The
global attributes of each GCN network, including number of samples, edges, and nodes,
before and after DEG filtering can be found in Table 3.1. Cytoscape was used to
visualize the UCEC, UCS, and GTEx GCN networks, which can be found in Figure 3.2,
Figure 3.3, and Supplemental Figure 3.1, respectively. All GCN nodes, edges and their
corresponding DEG status can be found in Supplemental Table 3.1.
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Differential Gene Expression Analysis. Differential gene expression analysis was
performed between GEMs of the normal uterine tissue of GTEx (v.6) and TCGA-UCEC,
as well as GTEx-Normal and TCGA-UCS. It was completed by DESeq2_1.30.1 in R 4.0
(https://bioconductor.org/packages/release/bioc/html/DESeq2.html). The RSEM raw
counts for the analysis were obtained from
(https://www.nature.com/articles/sdata201861:
https://doi.org/10.6084/m9.figshare.5330539). Prior to the analysis only genes with
RSEM values for at least fifty samples within each analysis were considered and in postprocessing the genes with an adjusted p-value > 0.05 were dropped. The results for the
UCEC and UCS DESeq analyses can be found in Supplemental Table 3.2 and
Supplemental Table 3.3, respectively.
GRN Construction. The Glass Lab at Harvard University published tissueassociated regulatory relationships for normal tissues based on data from the GTEx
project [https://sites.google.com/a/channing.harvard.edu/kimberlyglass/tools/gtexnetworks] (261). From this list of regulatory edges, those enriched in uterus were
extracted (N=60,915). These edges could have been uterus-specific or found in other
tissues in addition to uterus. The published uterine regulatory edges were merged with
each csGCN to create respective csGRNs containing both gene co-expression edges and
regulatory edges. In the GTEx-Normal and UCEC networks, several GCN genes were
also found to act as uterine transcription factors. These are denoted as ‘TF/gene’ nodes
throughout the GRN analysis.
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We were also interested in investigating possible co-regulation. To do this,
“triangle” relationships were extracted from the UCEC GRN. We define a triangle
relationship as one in which one transcription factor regulates two genes connected by an
edge. No triangle relationships were found in the UCS network, likely due to its smaller
size.
To further investigate the regulatory edges and their differences between cancer
and normal tissue, we performed a t-test on the FPKM ratio for the transcription factor
(TF) and target gene (TR). For each regulatory edge the FPKM values for the TF and TR
were collected for the corresponding cancer samples and GTEx-Normal samples. The
values underwent a t-test as ratios (TF/TR) to see if they were significantly different (pvalue < 1E-5) between the cancerous and normal tissues. This analysis was completed for
the regulatory edges in the UCEC, UCS, and the UCEC triangle GRNs.
Like the GCN analysis, the nodes of each regulatory edge were subject to a
differential expression analysis, performed like above. The number of samples, edges,
genes, TFs, TF/genes, and connectivity for the csGRNs can be found in Table 3.2. The
regulatory edges, the DEG status of the nodes, and the p-value from the ratio analysis for
the cancer-specific GRNs and GTEx GRN can be found in Supplemental Table 3.4 and
Supplemental Table 3.5, respectively.
Functional Enrichment. Functional enrichment was performed on the DEGs for
each csGCN (UCEC, UCS, UCEC triangle, and GTEx). This was done using ToppFun
(https://toppgene.cchmc.org/). The respective DEG lists were used as input for
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enrichment of each condition specific GCN, and the default gene set was used as the
background. The functional enrichment results can be found in Supplemental Table 3.6.
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CHAPTER FOUR
DISSERTATION SUMMARY, CONTRIBUTIONS, AND CONCLUSIONS
This Dissertation investigated genetic associations with two complex conditions:
ASD and uterine cancer. In Chapter 1 of this Dissertation, I introduced ASD and uterine
cancer, including their respective known genetic associations, as well as an overview of
the resources, techniques, and tools needed for further investigation into those complex
conditions. Chapter 2 dove into a DNA-based study where I discovered 30 regulatory
variants associated with ASD-affected individuals, investigated their classification
potential, and explored their associations with established brain annotations. Chapter 3
discussed an RNA-based study where condition-specific GCNs and GRNs were built and
analyzed using functional enrichment and differential expression analysis. Candidate
genes and transcription factors were then further studied for a better characterization of
the mutations and potential biological pathways involved in endometrial cancer.
While the significance of these studies is specific to each field, both studies
demonstrate how integral genomic resources and bioinformatic tools are to the discovery
and validation of condition-specific biomarkers. Transitioning from gene-focused studies
to whole genome investigations allows for a more comprehensive look at genetic changes
and their potential implications, especially when exploring complex conditions. The drylab approach to research not only requires access to whole-genome resources, but also the
necessary computational skills to analyze and interpret data.
In conclusion, this Dissertation reflects the time, effort, and problem-solving
skills I have developed while investigating complex conditions. During these studies

DNA and RNA condition-specific biomarkers have been identified for ASD and uterine
cancer using a variety of resources, as well as numerous bioinformatic tools and
techniques. However, there is still more to discover. In the future I would like to see more
resources dedicated to ensuring diversity within public datasets, as this would lead to
investigations into population-specific biomarkers for complex diseases and conditions.
An additional future direction would be to investigate the changes in gene expression of
various cancer types based on the type of treatment the individual underwent. Both
avenues will allow for a more comprehensive look into complex conditions, and therefore
advance the understanding of their genetic and biological associations.
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Appendix A
Supplementary Tables
Supplemental Table 2.1. SPARK-GTEx Experimental Results
Supplemental Table 2.2. SPARK-gnomAD Experimental Results
Supplemental Table 2.3. Significant Variants
Supplemental Table 2.4. Significant eQTLs
Supplemental Table 2.5. eQTL Summary by Tissue
Supplemental Table 2.6. SPARK ASD-Affected vs SPARK ASD-Unaffected
Experimental Results
Supplemental Table 3.1. Gene Co-expression Networks with DEG Annotations
Supplemental Table 3.2. Differential Expression Analysis Results Comparing UCEC and
GTEx
Supplemental Table 3.3. Differential Expression Analysis Results Comparing UCS and
GTEx
Supplemental Table 3.4. Cancer-Specific Gene Regulatory Networks
Supplemental Table 3.5. GTEx Gene Regulatory Network
Supplemental Table 3.6. GDC Mutation Rates of UCEC Triangle Genes and
Transcription Factors
Supplemental Table 3.7. Functional Enrichment Results for Differentially Expressed
Genes in Each Cancer-Specific Gene Expression Network
The supplemental tables can be found here.
DOI: https://doi.org/10.6084/m9.figshare.17071166
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Appendix B
Supplementary Figures

Supplementary Figure 2.1: tSNE Visualization of Individuals derived from the
Caucasian SPARK-GTEx Discovery Population. This plot includes the 90 SPARK
ASD-Affected individuals with the most severe phenotypic characteristics, the 90
SPARK ASD-Affected individuals with the least severe phenotypic characteristics, and
90 random GTEx ASD-Unaffected individuals at the 30 significant variants.
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Supplementary Figure 3.1: Cytoscape visualization of GTEx-specific network with
co-expression and regulatory edges. Gene co-expression and regulatory network for
normal uterine tissue.

Supplementary Figure 3.2: Heatmap of UCEC Regulatory Edges. First two rows
represent if the transcription factor and target gene are differentially expressed genes; red
denoting it is, and white represents it is not. If the transcription factor or target gene is
differentially expressed, it’s expression in UCEC is represented in the following two
rows. Red represents increased expression in cancer, blue represents decreased
expression in cancer, and white means the gene is not differentially expressed. The
bottom row details regulatory edges that have a significantly different transcription factor
to target gene ratio between UCEC and normal tissue. Red represents a significant
difference and white represents no significant difference.
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